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1. ABSTRACT 
 
Protein synthesis is a cellular process finely regulated during growth and development and its 
deregulation can lead to cell apoptosis or disease. Translational control is rate-limiting in 
cancer growth and translation initiation step is emerging as an attractive therapeutic target. 
eIF6 is an antiassociation factor that regulates the availability of active 80S. Its activation is 
driven by the RACK1/PKCβ axis, in a mTORc1 independent manner. We previously 
described that eIF6 haploinsufficiency causes a striking survival in the Eµ-Myc mouse 
lymphoma model, with lifespans extendend up to 18 months. microRNAs have been shown to 
regulate a wide range of biological processes destabilizing messenger RNAs and by 
repressing the translation of these mRNAs. Involvement of microRNAs in repression of 
translation suggests that they might be associated with polysomes. Here we screen for 1) eIF6 
expression in human cancers and 2) association of microRNAs with polysomes in Malignant 
Pleural Mesothelioma (MPM). We show that MPM tumors and a MPM cell line (REN cells) 
contain high levels of hyperphosphorylated eIF6. Enzastaurin is a PKC beta inhibitor used in 
clinical trials. We prove that Enzastaurin treatment decreases eIF6 phosphorylation rate, but 
not eIF6 protein stability. The growth of REN, in vivo, and metastasis are reduced by either 
Enzastaurin treatment or eIF6 shRNA. Molecular analysis reveals that eIF6 manipulation 
affects the metabolic status of malignant mesothelioma cells. Less glycolysis and less ATP 
content are evident in REN cells depleted for eIF6 or treated with Enzastaurin (Anti-Warburg 
effect). We propose that eIF6 is necessary for Malignant Mesothelioma growth, in vivo, and 
can be targeted by kinase inhibitors. Finally we found that the MPM miRNA signature was 
characterized also by differential miRNAs subcellular distribution. In particular, only some 
miRNAs were expressed in the polysomal pool with variability in miRNAs occupancy, 
indicating that some miRNAs can repress translation, while others cannot. Particularly, we 
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evidenced that polysome-bound miRNAs present a correlation with the cell cycle pathway in 
REN cell, a MPM epithelioid cell line, suggesting that their polysomal localization could 
explain how these miRNAs may regulate cell cycle components translation. 
  
3 
 
2. INTRODUCTION 
 
2.1 Malignant Mesothelioma 
 
Malignant mesothelioma is a rare but highly aggressive tumour and its mortality is one of the 
highest associated with cancers, up to 1% (Carbone, Albelda et al. 2007). There are two major 
localizations of malignant mesothelioma: the pleura and peritoneum, sporadically it may also 
arise in the pericardium or tunica vaginalis testis (Chekol and Sun 2012). 
 
2.1.1 Pleura: structure, functions and pathological conditions 
 
The chest cavity surrounds the heart and lungs and comprises the ribs, associated muscles and 
connective tissue. This cavity is covered by the parietal pleura, which is attached to the chest 
wall and by a continuous parietal mesothelial cell layer. The lungs themselves are enclosed by 
the visceral pleura which is integral to the lung surface and which has a surface visceral 
mesothelial layer. The close fitting of the lungs to the inside of the chest wall means that there 
is a thin space between the two mesothelial layers that contains the pleural fluid and a 
population of pleural macrophages (Donaldson, Murphy et al. 2010). The pleural mesothelial 
cells derive from the mesoderm and cover the surface in an epithelial-like manner, hence the 
word mesothelium (Michailova and Usunoff 2006). The normal mesothelial cell layer appears 
glistening, smooth, and semi-transparent. Mesothelial cells may vary from a row of flattened 
and elongated ovoid nuclei widely separated by cytoplasm to columnar or cuboidal cells with 
round basal nuclei and a cuboidal luminal surface (Batra and Antony 2015). These cells have 
microvilli and multiple intercellular adherens junctions and focal adhesions that anchor the 
mesothelial cell onto the extracellular membrane via integrins (Batra and Antony 2015). The 
connective tissue is intersected with blood vessels, lymphatic vessels, immune cells and 
fibroblast-like cells. It has been shown that fibroblast-like cells may differentiate and replace 
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the damaged mesothelium following injury (Mutsaers, Whitaker et al. 2002; Michailova and 
Usunoff 2006). In the pleural cavity between the two layers there is a small amount of fluid 
for lubrication that reduces friction between the visceral and parietal layers during breathing. 
This fluid is continuously circulating and is produced by the mesothelial cells and then 
drained into the lymphatic circulation. The pleural mesothelium also controls several tissue 
functions such as regulation of fibrinolysis, trans-membrane material flux, maintenance of 
serosal integrity by producing growth factors (GF) and extracellular matrix (ECM) 
components (Agostoni and Zocchi 2007). The most common growth factors found in the 
pleural space are vascular endothelial growth factor (VEGF), transforming growth factor β 
(TGFβ), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), hepatocyte 
growth factor (HGF) and heparin-binding epidermal growth factor-like growth factor. 
Common cytokines and chemokines include interleukins IL1, IL6, IL8 and IL15, SDF-1and 
prostaglandins (Michailova and Usunoff 2006).  
Many pathogens and carcinogens can hit pleura and cause cellular injuries; the consequent 
infections and inflammation led to big challenges in diagnosis and treatment (Murthy, Raja et 
al. 2012). Long-term inhalation of several natural and industrial fibers irritates the pleura 
causing chronic inflammation and scarring. Inflammation and injury result in cellular 
responses both from the immune system and the mesothelium itself (Cagle and Allen 2011). 
Cancers in the pleural cavity are often metastatic adenocarcinomas from other organs (Cagle 
and Allen 2011), as , stomach, breast, lung and ovary (Batra and Antony 2015), but there are 
also tumors arising from the pleural tissue (Cagle and Allen 2011). Solitary fibrous tumors of 
the pleura are mostly benign mesenchymal tumors without the standard mesothelial 
immunophenotype, but when malignant transformation occurs is highly difficult to 
distinguish it from the most common primary malignancy of pleural origin, the malignant 
pleural mesothelioma (Usami, Iwano et al. 2007) 
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2.1.2 Malignant Pleural Mesothelioma 
 
The pleural form of malignant mesothelioma is the most common type accounting for more 
than 70% of all mesothelioma cases (Chen and Pace 2012). Malignant pleural mesothelioma 
represents a common malignant disease (Ismail-Khan, Robinson et al. 2006) arising from 
mesothelial cells of the pleura and showing a close relationship with previous exposure to 
asbestos fibers. Asbestos is the most common causative agent for MPM (Yang, Testa et al. 
2008), with 80% of mesothelioma patients reporting asbestos exposure (Pass et al., 2008). 
However only a fraction of subjects exposed to high levels of asbestos develop MPM, 
suggesting that additional factors, such as genetic predisposition, may render some 
individuals more susceptible to asbestos carcinogenicity (Testa, Cheung et al. 2011). 
Recently, it has been reported that DAS, an artificial clay used as a toy and teaching material, 
contains a large amount of asbestos. This striking discovery changes the scenario of number 
of subjects exposed to asbestos fibers, showing that the presence of 30% of asbestos in DAS 
composition may cause exposure to a different variety of users, including teachers, artists and 
children. Since DAS has been used not only in Italy, it is essential that mesothelioma patients 
should be asked about their use of DAS, in particular if they do not report a past asbestos 
exposure (Silvestri, Di Benedetto et al. 2016). Wagner and colleagues were the first to 
describe the relationship between asbestos and MPM in 1960 when he published a series of 
MPM cases in asbestos mine workers from United States, Western Europe, South Africa, 
Japan, India, China, Australia, Indonesia and Vietnam (Porpodis, Zarogoulidis et al. 2013). 
This relationship is one of the clearest between a carcinogen and its associated cancer. 
Asbestos is a group of hydrated fibrous silicate minerals that occur in nature and is 
distinguished in two major groups: the white asbestos and the blue asbestos. The white 
asbestos include serpentines and chrysotile, instead the blue asbestos include the amphiboles, 
crocidolite and amosite (Yang, Testa et al. 2008). While white asbestos comprises 90% of the 
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world’s entire asbestos consumption, the blue form is the most carcinogenic (Yang, Testa et 
al. 2008). Due to its remarkable heat-resistant capacities, asbestos has been called a miracle-
fiber and has been extensively used in industry (Ismail-Khan, Robinson et al. 2006). The 
people most exposed to this carcinogen are therefore asbestos miners, plumbers, electricians, 
shipyard workers, construction workers and people in similar professions (Craighead 2011; 
Chen and Pace 2012). Since most asbestos exposure is work-related, mesothelioma is 
considered an occupational disease and, considering that asbestos exposure is more common 
in occupations with a predominantly male workforce, the incidence of MPM is higher among 
men than among women (5:1 ratio) (Nasreen, Khodayari et al. 2012). The risk fraction 
attributable to occupational asbestos exposure is lower than 40% in women and higher than 
80% in men. Environmental mesotheliomas are linked either with a natural exposure in areas 
in the world where asbestos exists as a geological components of the soil or with 
neighborhood exposure in people living close to asbestos factories or mines (van Meerbeeck, 
Scherpereel et al. 2011). The commercial use of asbestos peaked between 1930 and 1960 
(Kaufman and Pass 2008), but asbestos has been strongly restricted or banned, in several 
countries since then (Kao, Reid et al. 2010). Inhaled asbestos fibers accumulate in the 
mesothelium leading to a status of chronic inflammation and signaling activation, favoring the 
carcinogenic process (Yang, Rivera et al. 2010). Asbestos fibers of a certain length and width 
are inhaled all the way out to the alveoli. Over time, these fibers migrate out to both layers of 
the pleura. These fibers are like thin spears that can penetrate plasma membranes without 
killing the cells. Upon ingestion by macrophages and other cells the asbestos fibers become 
covered by iron-rich proteins and iron deposit. These ferruginous bodies may lead to 
increased formation of reactive oxygen species (ROS). ROS lead to cellular damage, 
especially DNA mutations, and have been linked to tumor progression (Wu 2006). 
Macrophages that try to phagocytize the asbestos fibers fail, but in the process produce more 
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cytokines and ROS. This is called frustrated phagocytosis and is part of a chronic 
inflammation in the lung and pleura (Wu 2006). Properties of the asbestos fibers and the 
increased ROS production during the inflammation process are thought to be some of the 
main biological causes of Malignant Pleural Mesothelioma. Incidence of MPM reach 100 
cases/million/year in occupationally exposed populations opposed to 1 case/million/year in 
the general populations (Porret, Madelaine et al. 2007), although there are prominent 
differences in incidence of MPM reported from different countries worldwide varying from 7 
per million (Japan) to 40 per million (Australia) inhabitants per year. In Europe the incidence 
is around 20 per million with large intercountry variation. It is logical that these differences 
are due to differences in historical asbestos import and consumption (Pass and Carbone 2009). 
All individuals who have been exposed to asbestos are considered as a population at risk. The 
mean latency of MPM after exposure to asbestos is around 30-40 years. The median age at 
diagnosis in Western countries is 69 years with an increasing fraction of patients with co-
morbidities (van Meerbeeck, Scherpereel et al. 2011). Although 50 years have passed since 
the discovery of the first incidence of MPM, an optimal strategy has not been yet established, 
as the diagnosis, staging and treatment remains highly complex.  
 
2.1.3 Pathogenesis, diagnosis and therapies of Malignant Pleural Mesothelioma 
 
The most common symptoms of MPM are shortness of breath and pain (90%), tiredness 
(36%), cough (22%), sweating (22%), worry (29%) and constipation (22%) (Muers, Stephens 
et al. 2008). There are three major histopathological subtypes of MPM: epithelioid (60%), 
sarcomatous (10%) and biphasic (30%). The phenotypes are closely linked to patient survival, 
the median survival time has been reported to fall from 12 months for epithelioid 
mesotheliomas, associated with the best prognosis, to only 4 months for sarcomatoid 
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mesotheliomas (Pinto, Novello et al. 2013). Given that the disease is infrequent and only a 
few pathologists have extensive experience with mesothelioma, the diagnosis is sometimes 
delayed (Porpodis, Zarogoulidis et al. 2013). The clinical procedure is first imaging with chest 
x-ray that can show the effusion and the tumor or pleural thickening. Computed tomography 
(CT) can show a pleural mass and invasion. More advanced imaging techniques, such as 
magnetic resonance imaging and positron emission tomography (PET) can be helpful in 
evaluating tumour likelihood, invasiveness and staging. Staging is useful in planning surgical 
management however is of little importance for medical management of malignant 
mesothelioma (Robinson, Musk et al. 2005). Video-assisted thoracoscopy is the best biopsy 
technique (accuracy of 98%) and cytology, a reliable diagnostic tool for experienced 
cytopathologists, can offer additional tissue confirmation. Thus, several 
immunohistochemical panels are proposed to distinguish between sub-types of mesothelioma, 
secondary carcinoma and other malignant tumors metastatic to serosal membranes 
(Henderson, Reid et al. 2013). Calretinin is the most commonly used antibody, positive for 
mesothelioma with a reported specificity of 87% and sensitivity of 95%. Other useful antigens 
include thrombomodulin, mesothelin and cytokeratin 5 (Yaziji, Battifora et al. 2006). 
Molecular genetic analysis has revealed three key genetic alterations in MPM: cyclin-
dependent kinase inhibitor 2A/alternative reading frame (CDKN2A/ARF), neurofibromatosis 
type 2 (NF2) and BRCA1-associated protein-1 (BAP1) genes. CDKN2A)/ARF gene is the 
most frequently inactivated tumor suppressor gene in human MPM (Musti, Kettunen et al. 
2006). CDKN2A encodes p16
INK4a
 whereas ARF encodes p14
ARF
. p16
INK4a
 controls the cell 
cycle via the CDK4/cyclin D retinoblastoma protein pathway, whereas p14
ARF
 regulates p53 
protein. The homozygous deletion of CDKN2A/ARF causes the inactivation of two major 
tumor suppressing pathways of retinoblastoma and p53 in the cell. It has been reported that 
MPM cases of epithelioid type showed ~70% of homozygous deletion of CDKN2A whereas 
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sarcomatoid type showed ~100% of homozygous deletion. Moreover, although p53 is the 
most frequently inactivated tumor suppressor genes in human malignancies, only a limited 
number of MPM cases show a p53 mutation. (Sekido 2013). It has been demonstrated that 
miR-31 is co-deleted with CDKN2A, and reintroduction of miR-31 in MPM cells shows a 
suppressive effect on mesothelioma cells (Ivanov, Goparaju et al. 2010). Mouse studies 
showed that mice deficient for Arf, but not p16
INK4a
, were susceptible to accelerated asbestos-
induced MPM (Altomare, Menges et al. 2009). Instead the inactivation of both Arf and 
p16
INK4a
 may cooperate to accelerate asbestos-induced tumorigenesis in vivo (Altomare, 
Menges et al. 2011). NF2 gene encodes merlin, a tumor suppressor protein that can be 
inactivated not only genetically but also with other mechanisms, such as phosphorylation of 
CPI-17, an oncogene product that inhibits the merlin phosphatase MYPT1-PP1 δ 
(Thurneysen, Opitz et al. 2009).  Merlin is able to regulate multiple cell signaling cascades 
including mTOR and the Hippo pathways, which regulate cell proliferation and growth. 
Furthermore, a study suggested that upregulation miR-885-3p might target NF2 (Guled, Lahti 
et al. 2009), however it still remains unclear how much these inactivation mechanisms are 
actually involved in MPM cases. To clarify the mechanism of NF2 mutation in MPM it has 
been developed a NF2 knockout mouse model. Asbestos exposed Nf2 (+/−) knockout mice 
exhibited accelerated MPM tumor formation compared with asbestos-treated wild-type 
(Altomare, Vaslet et al. 2005). Finally, BAP1 encodes a nuclear ubiquitin C-terminal 
hydrolase, a class of deubiquitinating enzymes. It has been implicated in various biologic 
processes including DNA damage, response and regulation of cell cycle and growth (Eletr and 
Wilkinson 2011). BAP1 is also involved in histone modification and its inactivation induces 
the impairment  of global gene expression profiling. Germline mutations of BAP1 gene were 
detected in two families with a high incidence of MPM and some BAP1 mutations occur in 
the families developed other types of tumors including uveal melanoma (Testa, Cheung et al. 
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2011). BAP1 was also shown to be frequently mutated in uveal melanomas of the eye 
(Harbour, Onken et al. 2010) and germline mutation of BAP1 was identified in families 
carrying melanocytic tumors (Wiesner, Obenauf et al. 2011).  It is an important tumor 
suppressor in multiple tissues and its germline mutation may have a causative role in uveal 
and cutaneous melanoma, mesothelioma, melanocytic BAP1-mutated atypical intradermal 
tumors and other cancers (Sekido 2013).  
Treatment of MPM can be classified into radical procedures such as surgery and into 
palliative measures which consist in the removal of pleural effusions and the preventing of 
their recurrence in order to relieve the symptoms such as dyspnea and chest pain (Porpodis, 
Zarogoulidis et al. 2013). Today, once the diagnosis is made, there are no accepted or 
published guidelines to establish a standard surgical approach, as extrapleural 
pneumonectomy and pleurectomy. It is a fact that surgery is not an option for the majority of 
the patients due to the diffuse spreading growth of this tumor (Porpodis, Zarogoulidis et al. 
2013). Moreover several factors should be taken into account concerning the choice of 
surgery treatment such as patient’s cardiopulmonary reserve, disease stage, surgeon’s 
experience and the extent of planned adjuvant therapy (Kaufman and Flores 2011). However, 
since the role of surgery as single-modality therapy in MPM remains controversial, the 
management of MPM consists of combinations between platinum-based chemotherapy, 
surgery and radiation. Similarly to surgical treatment, there is  no evidence of survival benefit 
concerning radical radiotherapy of the hemithorax when compared to best supportive care 
(Porpodis, Zarogoulidis et al. 2013). Actually, multimodality strategies include EPP or 
pleurectomy combined with adjunctive therapies such as immunotherapy, radiotherapy and 
chemotherapy. However, frequently, the only choice available is palliative treatment (West 
and Lee 2006). In locally advanced or metastatic disease, chemotherapy improves the quality 
of life and induces symptomatic relief. However the tumor is generally characterized by 
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chemoresistance, and it has been observed that most single agents exhibit low intrinsic 
activity (Montanaro, Rosato et al. 2009). The current standard first line therapy for systemic 
treatment of advanced MPM is represented by combined chemotherapy with cisplatin and 
antifolate. The median response rate to chemotherapy is only 30% and its impact on overall 
survival (OS) is negligible. According to a recent study run by Zalcman and colleagues, a 
phase 3 clinical trial showed that addition of bevacizumab to pemetrexed and cisplatin 
improved overall survival of malignant pleural mesothelioma, with tractable toxic effects, 
suggesting that it should be a new acceptable treatment for MPM (Zalcman, Mazieres et al. 
2015). Other approaches have been tested in MPM clinical trials, such as instillation of 
cytokines, antibodies, vaccines, immunogene therapy and adoptive transfer of T cell (Pinton, 
Manente et al. 2012).  
By now, several investigations are necessary to understand, on one hand how improving the 
quality patients life, on the other hand trying to define new therapies. 
 
2.2 Translation  
 
Protein synthesis, or translation, is essential for cell growth. It is regulated by ribosomes 
synthesis in the nucleolus and by ribosome usage in the cytoplasm. Translation is deregulated 
in cancer cells (Silvera, Formenti et al. 2010; Loreni, Mancino et al. 2014). Recent works 
have shown that the translational machinery plays an active role in transformation and tumor 
malignancy, suggesting that it can be a therapeutic target (Sonenberg 2008; Ruggero 2013). 
Translation is the cellular process in which mRNA, previously transcribed from DNA and 
processed, is decoded by ribosomes to make proteins. Ribosomes are constituted by ribosomal 
RNA (rRNA) and structural proteins. In Eukaryotes they are formed by a small subunit (40S) 
and by a large subunit (60S). The joining between 40S and 60S subunits generates a 
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translational competent ribosome (80S). Translation can be divided in four major steps: 
initiation, elongation, termination and ribosomal recycling. Each of these steps is assisted by 
protein factors - called eukaryotic initiation factors (eIFs), eukaryotic elongation factors 
(eEFs) and eukaryotic termination factors (eRFs), which transiently associate with the 
ribosome and/or the mRNA. Translation initiation consists of the events that led up to the 
positioning of an elongation-competent 80S ribosome at the start codon of the mRNA. 
Polypeptide synthesis takes place during the elongation phases. The completed polypeptide is 
released after the ribosome encounters a stop codon during translation termination (Lackner 
and Bahler 2008). The importance and complexity of translation initiation compared to 
elongation and termination is further underscored by the fact that only few dedicated factors 
are needed for the elongation and termination processes, whereas more than 25 proteins are 
needed to guarantee a  proper translation initiation (Holcik and Pestova 2007).  
2.2.1 Cap-dependent translation 
 
Translation initiation can be subdivided into four steps: 1) binding of the specific initiator 
Met-tRNA, to the small ribosomal subunit (40S), 2) binding of the formed complex to the cap 
structure at the 5’ end of mRNA, 3) scanning of the 5’untranslated region (5’UTR) of the 
mRNA and start codon recognition, 4) joining of the large ribosomal subunit (60S) to 
generate a translation competent ribosome (80S). As physiological conditions favor the 
association of 40S and 60S ribosomal subunit to form complete 80S ribosomes, but only free 
ribosomal subunits can initiate translation, it is important that post termination ribosomes 
dissociate (Preiss and Hentze 2003). The eukaryotic initiation factors eIF3, eIF1, eIF1A and 
eIF6 are thought to promote this dissociation in eukaryotes (Holcik and Pestova 2007). As 
reported in Figure 1, the first step in 43S preinitiation complex formation is the assembly of a 
ternary complex, consisting of eIF2, methionyl tRNA (met-tRNA) and GTP. Its assembly is 
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stimulated by the guanine nt exchange factor (GEF) eIF2B. GTP is hydrolyzed after 
recognition of the AUG start codon producing eIF2 bound to GTP (Sonenberg and 
Hinnebusch 2007). eIF2B promotes GDP-GTP exchange to regenerate active eIF2. Binding 
of the ternary complex to the 40S ribosomal subunit is supported by eIF1, eIF1A and eIF3 in 
mammalian cells (Preiss and Hentze 2003; Holcik and Pestova 2007). The 43S preinitiation 
complex is ready to bind to the 5’ end of the mRNA.  
 
Figure 1. Cap-mediated translation initiation (Gebauer and Hentze 2004) 
 
The eIF4F complex bounds to the 5’m7GpppN cap structure and promotes the recruitment of 
the 43S preinitiation complex to the 5’end of the mRNA generating a complex called 48S. 
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eIF4F is composed of the cap-binding protein eIF4E, the scaffold protein eIF4G and the ATP-
dependent helicase eIF4A that, assisted by eIF4B, unwinds secondary structures in the 5’UTR 
of the mRNA. The binding of the preinitiation complex to the mRNA involves the 
cooperative activities of eIF4F, eIF3, eIF4B and PABP. PABP was identified as a protein that 
associated with polyA tail at the 3’UTR of the mRNA. The PABP-eIF4G interaction is 
thought to promote a circularization of the mRNA molecule forming a closed loop. This 
circularization provides a possible framework by which 3’UTR-binding proteins can regulate 
translation initiation (Gebauer and Hentze 2004). Once assembled near the 5’ end of the 
mRNA, the 48S complex scan along the mRNA to find the AUG starts codon. In eukaryotes, 
recognition of an AUG as a start codon critically depends on its surrounding sequence. The 
scanning process requires ATP and a study using a reconstitute mammalian translation 
initiation system suggests that this requirement reflects the necessity of unwinding secondary 
structures in the 5’ UTR by the eIF4A and eIF4B RNA helicases (Pestova and Kolupaeva 
2002). Furthermore eIF1 and eIF1A have been shown to play an important role in the 
scanning process as well as in the recognition of the corresponding initiation codon. Several 
events take place in order for the 60S subunit to join the 48S complex and form the 80S 
ribosome. Joining of the 60S ribosomal subunit to the 48S complex requires hydrolysis of two 
GTP molecules. First, eIF5 triggers GTP hydrolysis by eIF2, which leaves the complex 
thereafter in the GDP bound state together with eIF5 (Unbehaun, Borukhov et al. 2004). eIF1 
and eIF3 remain associated with the complex until eIF5B, a second GTPase, binds to the 43S 
preinitiation complex and allows the 60S subunit to join. Finally, GTP hydrolysis in eIF5B, 
triggered by 60S subunit joining, results in the dissociation of eIF5B in the GDP bound form 
and the formation of an elongation competent 80S ribosome (Pestova, Lomakin et al. 2000). 
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2.2.2 The translational regulation 
 
Protein synthesis, in comparison to the other biosynthetic processes, is the most energetically 
expensive process going on within the cells; therefore translation has to be highly regulated. 
Translational regulation is involved in the response to cellular stress (Holcik and Sonenberg 
2005), in the misregulation of gene expression during cancer, in apoptosis and in development 
(Hinton, Coldwell et al. 2007). The need for translational control is also important for systems 
where transcriptional control is not possible, such as RNA viruses and reticulocytes, where 
the nucleus is absent. These systems provided us much of our understanding of translational 
regulation, e.g. reticulocytes are the most efficient cell-free protein synthesis in vitro. 
Translational regulation can be divided into global regulation of translation and mRNA 
specific regulation (Gebauer and Hentze 2004): global regulation affects the translation 
efficiency of most mRNAs through a general tuning of translation, while mRNA specific 
regulation affects the translation of specific mRNAs. Global regulation of translation is 
generally mediated through modifications of translation initiation factors that transform the 
information from external compartments to the cell. Initiation phase of translation is the 
limiting step for a given mRNA, and initiation factors act as regulators, downstream of 
signaling events (Sonenberg and Hinnebusch 2009). Certain mRNA can be specifically 
regulated, usually by proteins that bind to cis-regulatory sequences present in 5’ and/or 3’ 
UTRs of a given mRNA. The ribosome itself can be targeted to exhert translational 
regulation, and several of its protein constituents can stand posttranslational modifications 
(Lackner and Bahler 2008). 
Regulation of ternary complex formation. One of the best studied examples of the 
translational downregulation is the control of the active ternary complex formation. Binding 
of Met-tRNAi
Met
 to the 40S subunit through the ternary complex is an essential step in 
translational initiation. After the exposure to stress, the α-subunit of eIF2 (eIF2α) is 
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phosphorylated and inhibits the exchange GDP-GTP by eIF2B, and the formation of active 
ternary complexes is highly reduced, downregulating global translation (Holcik and 
Sonenberg 2005; Oyadomari, Harding et al. 2008) (Figure 2).  
 
Figure 2. Integration of stress responses by the phosphorylation of eIF2α (Holcik and Sonenberg 
2005). 
 
Induction of p-eIF2α serves as an important regulator, under which general protein synthesis 
and cell proliferation are blocked, thus allowing cells to recuperate from stress or be 
eliminated if the damage is beyond repair (Koromilas 2015).  Phosphorylation of eIF2α is 
mediated by PKR, an interferon (IFN)-inducible protein with pro-inflammatory and antiviral 
properties, which is activated by binding to double-stranded (ds) RNA; a family of kinases 
consisting of the heme-regulated inhibitor (HRI), which is activated by heme deficiency; the 
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endoplasmic reticulum (ER)-resident protein kinase PERK/PEK, which is activated by the 
accumulation of misfolded proteins in the ER; and finally the general control non-
derepressible-2 (GCN2), which is activated by accumulation of uncharged tRNAs caused by 
amino-acid or nutrient deprivation (Chen 2007; Koromilas 2015). Phosphorylation of the α-
subunit of eIF2 inhibits the GDT-GTP exchange reaction mediated by eIF2B due to a reduced 
dissociation of eIF2 from eIF2B. As a result, less eIF2B is available to promote GDP-GTP 
exchange and global translation is inhibited (Holcik and Sonenberg 2005). 
Regulation of cap-dependent translation and mTOR pathway. Most of the cap-dependent 
translation is regulated by the pathway of the mammalian Target of Rapamycin (mTOR). 
mTOR is an evolutionarily conserved Ser/Thr kinase, which regulates proliferation and 
growth in response to cellular energy status, growth factors, hormones, and nutrient 
availability (Zoncu, Efeyan et al. 2011). mTOR exists in two functionally and structurally 
distinct protein complexes: mTOR complex 1 and 2 (mTORC1 and mTORC2). These two 
complexes regulate disparate cellular functions by phosphorylating distinct sets of substrates. 
Several substrates of mTORC1 have been identified including the eIF4E-binding proteins 
(4E-BPs), S6 kinases 1 and 2 (S6Ks), PRAS40, Ser/Thr kinase Ulk1 (also known as hATG1), 
and growth factor receptor-bound protein 10 (Grb10) (reviewed by (Caron, Ghosh et al. 
2010). The function, the upstream regulators and the associated substrates of mTORC2 are 
less understood (Oh and Jacinto 2011). mTORC2 phosphorylates AGC kinase family 
members  and controls cytoskeletal organization and cell survival (Guertin and Sabatini 2007; 
Garcia-Martinez and Alessi 2008). mTORC2 also associates with the ribosome (Zinzalla, 
Stracka et al. 2011) where it phosphorylates residues in nascent polypeptide chains that are 
important for optimal protein folding (Oh, Wu et al. 2010). mTORC1 plays a central role in 
the regulation of proliferation and cell growth (Ma and Blenis 2009), cellular processes that 
are directly proportional to translational activity. Hormones, growth factors and glucose 
18 
 
stimulate mTORC1, up-regulate translation and stimulate cellular growth and proliferation. 
Conversely, under conditions in which energy production, oxygen supply and nutrients are 
inadequate, mTORC1 signaling is down-regulated, resulting in inhibition of translation, 
reduction in cellular growth proliferation, and induction of autophagy. Rapamycin is a 
naturally occurring allosteric inhibitor of mTORC1 (Guertin and Sabatini 2007). mTOR 
inactivation, by treatment with rapamycin, mimics deprivation of nutrients, both in mammals 
and in yeast. Main downstream targets of mTOR kinase are eIF4E-binding proteins (4E-BPs), 
rpS6 kinases (S6K) and eEF2 kinase (Hay and Sonenberg 2004). 4E-BPs and S6Ks are the 
most extensively studied and best-understood downstream effectors of mTORC1, which have 
been implicated in the regulation of translation (Figure 3). 
 
Figure 3. mTOR signaling pathway (Populo, Lopes et al. 2012) 
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The first step of cap-dependent translation initiation is the assembly of the eIF4F complex on 
the mRNA cap structure (Topisirovic and Sonenberg 2011). eIF4E binds to the 5’ cap 
structure of eukaryotic mRNAs and provides the first contact between the translational 
machinery and the mRNA in de novo translation initiation. eIF4E interacts with several types 
of protein binding partners. It binds the scaffold protein eIF4G, which in turn, interacts with 
the RNA helicase eIF4A, the multisubunit eIF3 which provides the association to the 40S 
subunit, and the poly (A)-binding protein (PABP). The eIF4E/4G/4A complex is referred as 
the eIF4F complex which is thought to be of key importance in mediating normal, cap-
dependent translation initiation. A second group of eIF4E binding proteins comprises low 
molecular mass proteins that block its interaction with eIF4G. In mammals three eIF4E 
binding proteins are known, 4E-BP1/2/3. 4E-BPs interferes with the assembly of the eIF4F 
complex by competing with eIF4G for binding to eIF4E. On activation, mTORC1 
phosphorylates residues corresponding to Thr37 and Thr46 on human 4E-BP1, which act as 
priming sites for the phosphorylation of Ser65 and Thr70. Phosphorylation of 4E-BPs on 
these four residues, leads to their dissociation from eIF4E, allowing the assembly of the eIF4F 
complex. In addition to 4E-BPs, TOR regulates translation by activating the S6Ks (Ma and 
Blenis 2009). Although Drosophila expresses a single S6K protein (dS6K), mammals express 
two variants of S6K (S6K1 and S6K2). rpS6 was the first identified S6K substrate. Five 
phosphorylation sites (Ser235, Ser236, Ser240, Ser244, and Ser247 in humans and rodents) 
are clustered in the carboxyl terminus of rpS6 (Meyuhas 2008). It has been demonstrated that, 
using S6K1/S6K2 double knockout mice, both S6K1 and S6K2 isoforms contribute to the 
regulation of basal and inducible rpS6 phosphorylation at S235/236 and S240/244 sites 
(Pende, Um et al. 2004; Chauvin, Koka et al. 2014). Notably, S6K2 knockout mice display a 
reduction of rpS6 phosphorylation only at S235/236 while S6K1-deficient mice show no 
alterations (Bhattacharya, Kaphzan et al. 2012). Several studies have demonstrated that S6K1 
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regulates translation initiation through the phosphorylation of the cap binding complex 
component eIF4B at S422 (Raught, Peiretti et al. 2004). Finally, for many years it has been 
believed that the phosphorylation of rpS6 had an effect on the translation of a specific subset 
of mRNAs bearing a 5′ terminal oligopyrimidine tract (TOP). Actually, this model has been 
changed by studies showing that both double mutant S6K1/2 MEFs and  rpS6 knockin mouse 
exhibit normal TOP translation (Ruvinsky, Sharon et al. 2005).  
Regulation of cap independent translation (IRES) 
An important mode of translational regulation during stress is the selective recruitment of 
mRNA through internal ribosome-entry site (IRES). The IRES directly recruits ribosomes, 
bypassing the requirements for the mRNA 5’ cap structure and eIF4E (Johannes and Sarnow 
1998; Hellen and Sarnow 2001). Expression of genes bearing IRES elements in their mRNAs 
is controlled by multiple molecular mechanisms, with IRES-mediated translation favored 
when cap-dependent translation is compromised (Komar and Hatzoglou 2011). The 
translation initiation of several IRES-containing mRNAs occurs predominantly during stress 
and apoptosis (Holcik and Sonenberg 2005). By this alternative mechanism, even if cap-
dependent translation is reduced, some cellular mRNAs can be efficiently translated (Figure 
4). Kozak points out that evidence cited in support of the internal initiation hypothesis is often 
flawed, in fact, when putative IRESs are examined more carefully, they often turn out to 
harbor cryptic promoters or splice sites (Kozak 2005). Nevertheless it is clear that IRES-
mediated translation is used relatively frequently under both normal physiological and 
pathological conditions. 
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Figure 4. Cap dependent (a) versus IRES dependent (b) translation initiation (Komar and 
Hatzoglou 2011) 
 
Other mechanisms of mRNA translational regulation 
Of great importance in the translational mechanism are some regulatory sequences 
represented by upstream open reading frame (uORF), which interferes with the expression of 
the CDS. uORFs,  particularly common in transcripts for oncogenes and growth factors, are 
present in 10% of mRNAs (Sachs and Geballe 2006). uORFs interpose a barrier to prevent 
ribosomal access to initiation codon, preventing so the translation of the downstream ORF 
and affecting gene expression and mRNA stability. Even if the ribosome recognizes an 
initiation codon and translates the uORF, it might reinitiate at a downstream AUG codon 
thereby overcoming the barrier, typically in conditions of reduced translation driven by 
impaired eIF2-GTP-Met-tRNA ternary complex formation during specific cellular stress, as 
amino acid deprivation and unfolded protein response (UPR) (Baird and Wek 2012). For 
instance, when misfolded proteins accumulate in ER, eIF2α may be phosphorylated by PERK 
causing a reduction in global translation and favoring reinitiation at downstream ORF 
(Sonenberg and Hinnebusch 2009). 
Several lines of evidence indicate that mRNAs exist in an actively translated and associated 
with polysomes form and in a translationally repressed and associated with P-bodies state. 
The idea that the recruitment of mRNAs to P-bodies interferes with translation initiation is 
supported by the finding that inhibition of translation elongation causes P-bodies to disappear, 
while inhibition of translation initiation increases the size and number of P-bodies. In 
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mammalian cells, several proteins with established roles in translational repression localize to 
P-bodies: eIF4E inhibitory protein eIF4E-T, RCK/p54 and CPEB (reviewed by (Decker and 
Parker 2012). The exact mechanism of how mRNAs shuttle into P-bodies and become 
translationally repressed is yet unknown. 
 
2.2.3 Novel concepts in translational control: regulation by microRNA 
 
miRNA biology is associated, in the last years, to translation mechanism. microRNAs are 
short non coding RNA of 21-26 nt emerged as key posttranscriptional regulators of gene 
expression in metazoan animals, plants, and protozoa. Current studies estimate that human 
genome encodes hundreds of different miRNAs and that they could regulate almost the 60% 
of all genes (Friedman, Farh et al. 2009). In animals, miRNAs form imperfect hybrids with 
sequences in the mRNA 3’-untranslated region (3’ UTR), with the miRNA 5’-proximal 
“seed” region (positions 2–8) providing most of the pairing specificity (reviewed in (Bushati 
and Cohen 2007; Filipowicz, Bhattacharyya et al. 2008). Until very recently, it appeared that 
plant miRNAs generally base-pair to mRNAs with perfect complementarity and trigger 
endonucleolytic mRNA cleavage by the RNA interference (RNAi) mechanism. Generally, the 
binding partially complementary to target mRNAs, leads to mRNA degradation and 
translation inhibition
 
(Iorio and Croce 2012) recruiting the decapping and deadenylating 
machinery. Recently, however, some reports identify miRNAs as activator of mRNA 
translation during cell quiescence (Vasudevan, Tong et al. 2008; Niepmann 2009), as reported 
for miRNA 369-3: the direct base pairing between miRNA 369-3 and its target is required for 
translational upregulation after serum starvation (Vasudevan, Tong et al. 2008). Most studies 
affirm that miRNA mechanism acts at initiation of translation and can work as tumor 
suppressor or accelerating factor. The example of tumor suppressor is represented by miR-21 
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whose targets are PI3K and the apoptotic pathways
 
(Loreni, Mancino et al. 2014). In addition 
to classical tumor suppressor and oncogene functions, miRNAs can be also implicated in cell 
migration and metastasis, as the highly expressed miR10-b in metastatic breast cancer that 
positively regulates cell migration and invasion
 
(Ma, Teruya-Feldstein et al. 2007). miRNAs 
associate with Ago proteins to form RNA-induced silencing complexes (RISCs), through 
which they can modulate gene expression components. Components of miRISC and repressed 
mRNAs are enriched in processing bodies, which are cytoplasmic structures involved in the 
storage or degradation of translationally repressed mRNAs. Some P-bodies components are 
important for effective repression of protein synthesis by miRNAs. Recently, multivesicular 
bodies (MVBs) and endosomes were also identified as cellular organelles contributing to 
miRNA function or miRISC turnover (reviewed in (Fabian, Sonenberg et al. 2010). 
Regulation of gene expression via small RNAs and sequestration to P bodies, and interplay 
between miRNA translation inhibition and mRNA decay add further complexity to cellular 
posttranscriptional control. As 60% of genes are potential miRNA targets (Lewis, Burge et al. 
2005), miRNAs could exhert their function in a dual way: a mRNA could be regulated by 
several miRNAs and a miRNA could target several mRNAs. Moreover, both their expression 
and action is cell and tissue specific, as microRNA can target different mRNAs in different 
cell and tissues. This implicates that the action of microRNA is not conserved, but depends 
from its environment. Elucidation of the molecular events behind these mechanisms is 
needed.  
2.3 Eukaryotic Initiation Factor 6 (eIF6) 
 
Eukaryotic Initiation Factor 6 is an evolutionary conserved protein. The primary sequence 
shows two main features: 1) the protein is 245 aa long and it is 77% identical between 
humans and yeast (Biffo, Sanvito et al. 1997), 2) eIF6 primary sequence is evolutionarily 
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unique, with no conserved motifs. eIF6 structure has been solved, according to X-ray data: it 
is a rigid protein organized with a cyclic fold,  called pentein or star-like structure, formed by 
5 stretches of α/β subdomains arrayed about a five-fold axis of psuedosymmetry (Groft, 
Beckmann et al. 2000). The structure encloses a cavity that contains sixteen well-ordered 
water molecules, with limited degree of motility (Figure 5). 
 
 
Figure 5. Structure of eIF6. The protein has a unique star-like structure known as pentein, 
which is formed by five quasi identical subdomains (A–E) (Groft, Beckmann et al. 2000). 
 
Structural data have identified that eIF6 binds to intersubunit space of the large ribosomal 
subunit (Klinge, Voigts-Hoffmann et al. 2011). It is able to interact with the hydrophobic C-
terminal chain of the ribosomal protein L23 (rpL23). The sarcin-ricine loop and rpL24 also 
contribute to the interaction of eIF6 with the 60S subunit. Since the steric hindrance, it 
prevents binding between 60S and 40S.  
The semiconserved C-terminal tail seems a candidate region for eIF6 regulation and transport 
due to its flexibility. The C-terminus of eIF6 is characterized by the presence of many 
phosphorylation sites that are highly conserved in mammalian cells (Figure 6). 
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Figure 6. eIF6 phosphorylation sites (http://www.phosphosite.org) 
 
The phosphorylation sites Ser174 and Ser175 are located at the accessible surface of eIF6, not 
involved in the interaction with the 60S subunit. Also the flexible C-terminal sequence that 
contains Ser235 phosphorylation site is located at the outer surface of eIF6 (Gartmann, Blau 
et al. 2010). Mutation of the yeast homologues of eIF6, called Tif6p, at Serine-174 to Alanine 
reduced phosphorylation drastically and caused loss of cell viability and growth. When both 
Ser-174 and Ser-175 were mutated to alanine, phosphorylation of Tif6p was abolished. 
Furthermore, while wild-type Tif6p was distributed both in nuclei and the cytoplasm of yeast 
cells, the mutant Tif6p, containing Ser174Ala and Ser175Ala, became a constitutively nuclear 
protein (Basu, Si et al. 2003). Several studies have shown that eIF6 has a dual function: it is 
necessary for the maturation of 60S ribosomal subunit in the nucleus and possesses a 
ribosomal antiassociation activity (Miluzio, Beugnet et al. 2009), and it is involved in 
translation in the cytoplasm (reviewed by Biffo et al., A. Parsyan ed., 2014).  
Data collected through genomic sequencing projects reveal that evidences for eIF6 gene 
duplication do not exist, suggesting a strong evolutionary pressure for control of the protein 
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concentration. Human eIF6 gene is constitutively expressed in vitro, but modulated in vivo, 
since protein level in vivo are variable among different organs. Studies on levels of eIF6 in 
several metazoan tissues show that the protein is expressed at low level in muscle and high in 
brain. Furthermore, eIF6 is particularly expressed in stem cells or in cycling cells, but 
undetectable in some postmitotic cells (Donadini, Giodini et al. 2001). 
 
2.3.1 eIF6 on ribosome biogenesis and antiassociation activity 
 
Ribosome biogenesis is a very important process that occurs in the nucleolus and leads to the 
production of large and small mature ribosomal subunits and to their export to the cytoplasm. 
The small and large subunit are separately processed and exported, although they derived 
from the same rRNA precursor (47S in mammals). The large subunit matures through 
intermediate steps known as 90S-66S-pre60S-60S. Several lines of direct and indirect 
evidences support the necessity of eIF6 in ribosome biogenesis. Deletion of the yeast 
homolog Tif6 leads to a loss of the 60S ribosomal subunit that can be rescued by the ectopic 
expression of human eIF6 (Sanvito, Piatti et al. 1999; Si and Maitra 1999; Brina, Grosso et al. 
2011). Moreover biochemical evidences converge to the role of eIF6 in ribosome biogenesis. 
The protein is identified in molecular complexes from 66S to mature 60S. In agreement with 
this finding, a pool of eIF6 is localized in the nucleolus of both yeast and mammalian cells 
(Sanvito, Vivoli et al. 2000). The molecular mechanism by which eIF6 regulates 60S 
biogenesis is not completely clear. rRNA pulse-chain has shown that yeast cells depleted of 
eIF6 have defective pre-RNA processing. This causes the reduced formation of mature 25S 
and 5.8S rRNA relative to 18S rRNA, which may account for the selective deficit of 60S 
ribosomal subunit. Thus, eIF6 acts in biogenesis of 60S subunit, rather than in its stabilization 
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(Basu, Si et al. 2001; Woolford and Baserga 2013). However, our knowledge of the eIF6 
function in the biogenesis of 60S subunit is not clear and requires further studies.  
Moreover, eIF6 has a relevant biochemical activity, preventing binding of 40S and 60S in the 
absence of mRNA and thus avoiding an accumulation of inactive 80S subunit. In this way 
eIF6 is able to keep the small and large subunit available for initiation of translation (reviewed 
by Biffo et al., A. Parsyan ed. 2014). eIF6 was initially identified on the basis of its 
antiassociation activity in calf liver (Valenzuela, Chaudhuri et al. 1982) and wheat germ 
(Russell and Spremulli 1979), but it cannot dissociate preformed 80S complexes. It has been 
published the crystal structure of the 60S ribosomal subunit in complex with eIF6 in 
Tetraymena termophyla (Klinge, Voigts-Hoffmann et al. 2011). The structure reveals 
interactions between eukaryotic specific ribosomal proteins in the stabilization of the active 
site. The site of the eIF6 binding to 60S was mapped to the 40S-60S interface, close to sarcin-
ricin loop (SRL) and ribosomal protein rpL23 e rpL24, where it would prevent binding of the 
40S subunit. It is rationale to speculate that the antiassociation activity of eIF6, as observed in 
vitro, is relevant for translational control in vivo (Biffo et al., A. Parsyan ed. 2014). 
Furthermore, although eIF6 is dispensable for translation in vitro, low concentrations of eIF6 
have a slight stimulatory effect on translation, whereas higher concentrations inhibit it 
(Russell and Spremulli 1979). 
 
2.3.2 eIF6 and translation 
 
Ceci et al showed that eIF6 is able to repress translation after binding to 60S ribosomal 
subunit and similar observations were made with eIF6 bound to 50S (Benelli, Marzi et al. 
2009). Furthermore, mammalian and yeast eIF6 have common properties, such as the mainly 
cytoplasmic localization, which correlates with a role of eIF6 in the control of translation.  
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Since the binding of eIF6 to the large ribosomal subunits is able to affect translational 
initiation, it is possible to assume that there is a mechanism that favors its release leading to 
dissociation of eIF6 from the 60S ribosomal subunit. Two models for eIF6 release have been 
proposed: 1) 60S, bound to eIF6, is translocated from the nucleus to the cytoplasm. Here, the 
interaction between the Swachman-Bodian-Diamond Syndrome protein (SBDS) and the 
GTPase Efl1p with the 60S subunit leads to an allosteric change of 60S mediating the release 
of eIF6 (Wong, Traynor et al. 2011). This mechanism is relevant during the maturation step of 
the 60S subunit (Bussiere, Hashem et al. 2012). 2) Release of eIF6 is mediated by 
RACK/PKC complex. RACK1 acts as a scaffold receptor protein for active PKC and binds to 
the small ribosomal subunit (Ceci, Gaviraghi et al. 2003; Volta, Beugnet et al. 2013). 
Activated PKC translocates from endomembrane to the small subunit, comes in vicinity with 
eIF6 bound to 60S subunit and catalyzes the phosphorylation of eIF6 on Ser235 and its 
subsequent release (Brina, Grosso et al. 2011) (Figure 7). 
 
 
Figure 7. The two models of eIF6 release that regulate the interaction of the two ribosomal 
subunits. 
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Mouse model of eIF6 haploinsufficiency evidence that eIF6 is critical for translation initiation 
(Gandin, Miluzio et al. 2008). eIF6-null mice are embryonic lethal in mammals, but 
heterozygous mice, presenting a 50% of the eIF6 protein level, are viable. This reduction of 
the protein affects the cytoplasmic pool, and not the nuclear levels, leading to a proper 
biogenesis of the 60S ribosomal subunit. This confirm the notion that the function of the 
protein is cytoplasmic, translation related, and not nuclear, ribosomal biogenesis-related. The 
analysis of polysomal profiles of eIF6 heterozygous mice shows an increase in the 80S peak 
and a decrease in polysomes, confirming the role of eIF6 in initiation of translation. All 
mouse tissues of heterozygous mice have levels of the eIF6 protein reduced of 50% compared 
to the wild-type controls. The liver of eIF6 heterozygous mice shows an accumulation of 
inactive 80S complexes, and hepatocytes have normal level of translation but are not able to 
regulate its response to insulin. Thus full levels of eIF6 are necessary to perform the 
translation program induced by insulin of the cell, in vivo.  The expression of eIF6 is rate 
limiting for tissue growth, as mice haploinsufficient for eIF6 have smaller livers than wild-
type and reduced white fat mass. The deficit in insulin-stimulated translation occurring in 
eIF6+/– cells correlates with a high insulin sensitivity in tissues. Hepatocytes, fibroblasts and 
adipocytes from heterozygous eIF6 cells show a delayed G1-to-S phase progression but are 
normal in size, and have normal apoptosis and senescence (Gandin, Miluzio et al. 2008). 
 
2.3.3 eIF6 and cancer 
 
The research into the role in of eIF6 in cancer is still in the twilight. In tumors oncogenic 
pathways that promote tumor development and cellular transformation are hyperactivated and 
deregulation in translational control are endpoint of these these pathways (Silvera, Formenti et 
al. 2010). eIF6 is overexpressed in several cancer types, such as head and neck cancer (Rosso 
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et al., 2004), lung metastasis (Martin, Sanz et al. 2008), acute promyelocitic leukemia (Harris, 
Ozpolat et al. 2004) and malignant mesothelioma (Biffo, Sanvito et al. 1997). The mechanism 
that explains the eIF6 overexpression in cancer is unclear. eIF6 overexpression may reflect an 
increased demand for the protein by proliferating cancer cells, and not its role in etiology and 
cancer development. Cells with halved level of eIF6 protein show a reduction in MYC or 
HRAS-mediated oncogenic transformation (Gandin, Miluzio et al. 2008). MYC-induced 
lymphomagenesis is reduced in murine lymphoma with reduced eIF6 levels resulting in 
prolonged tumor free survival in the absence of negative side effects (Miluzio, Beugnet et al. 
2011). Mutation of eIF6 in the PKC consensus site Ser235 reduces the rate of transformation, 
suggesting its role in tumorigenesis (Miluzio, Beugnet et al. 2011). The most relevant 
information related to the regulation of the eIF6 activity by signaling are: 1) eif6 is 
hyperphosphorylated in cancer cells, in the C-terminus at Ser235, Ser239 and Thr243 (Ceci, 
Gaviraghi et al. 2003; Dephoure, Zhou et al. 2008); 2) mutation of Ser235 to Ala reduces 
translation and tumorigenesis (Gandin, Miluzio et al. 2008; Miluzio, Beugnet et al. 2011); 3) 
eIF6 activity is independent from mTORC1 activation but essential for growth factor and 
insulin activation (Gandin, Miluzio et al. 2008); 4) eIF6 interacts with RACK1 (Ceci, 
Gaviraghi et al. 2003; Guo, Wang et al. 2011), which is able to affect translation (Volta, 
Beugnet et al. 2013). The PKC isoform that binds RACK1 is PKCβ, and only the PKCβII 
isoform show a higher affinity for RACK1 receptor (Stebbins and Mochly-Rosen 2001). 
Moreover PKCβ inhibition reduces translation not affecting mTORC1 targets (Grosso, Volta 
et al. 2008), suggesting a role for the PKC axis in the regulation of translation. However it is 
possible that eIF6 activity is affected by mTORC2, upstream of several PKCs (Hagiwara, 
Cornu et al. 2012). These data suggest a role of eIf6 as a modulator of tumorigenesis and 
tumor growth.  
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2.4 MicroRNAs 
 
microRNAs are endogenous, small non-coding single-stranded RNAs of ~22 nucleotides in 
length, found in both plants and animals. They act as negative regulators of gene expression in 
several cellular processes and, in mammals, they are able to control the activity of more than 
60% of all protein-coding genes (Friedman, Farh et al. 2009). miRNAs regulate protein 
synthesis by base-pairing to target mRNAs. In animals, miRNAs form imperfect hybrids with 
sequences in the 3’UTR of mRNA, with the miRNA 5’-proximal “seed” region (positions 2–
8) providing most of the pairing specificity. In contrast plant miRNAs base-pair to mRNAs 
with perfect complementarity and trigger mRNA cleavage by the RNA interference (RNAi) 
mechanism (Filipowicz, Bhattacharyya et al. 2008; Bartel 2009). This is the typical strategy 
used by miRNAs to reduce the translation and stability of mRNAs, including those of genes 
that mediate processes in tumorigenesis, such as cell cycle regulation, inflammation, stress 
response, differentiation, apoptosis and invasion (Iorio and Croce 2012).  
miRNAs were originally shown to be important in timing of larval development in  C. 
Elegans , leading to the identification of the best known miRNAs lin-4 and let-7. Initial 
understanding of miRNA-mRNA target recognition came from observations of sequence 
complementarity of the lin-4 RNA to multiple conserved sites within the  lin-14  3’UTR; 
molecular genetic analysis showed that this complementarity was required for the repression 
of  lin-14 by lin-4 (Lee, Feinbaum et al. 1993; Wightman, Ha et al. 1993; Reinhart, Slack et 
al. 2000). 
microRNA biogenesis is divided into two main processing steps that take place in the nucleus 
and in the cytoplasm: primary microRNAs are first processed into the nucleus by RNAse III 
Drosha, associated to the double stranded RNA-binding protein DGCR8 (DiGeorge syndrome 
critical region gene 8; Pasha in flies) known as the microprocessor complex, that generates a 
~70 nucleotides precursor miRNA products, which fold into stable secondary stem-loop 
32 
 
structures. The latter are recognized by the Ran-GTP-dependent transporter Exportin 5, which 
mediates the translocation to the cytoplasm. Here Dicer, a RNAse III enzyme, associated to 
TRBP (TAR RNA-binding protein) and Argonaute proteins (AGO1-4), cleave the miRNA 
precursor hairpin and generate a transitory miRNA/miRNA* duplex (also named respectively 
miR-3p/miR-5p), which includes the mature miRNA guide, selected by thermodynamic 
properties, and the complementary passenger strand, usually subjected to degradation. This 
duplex is then loaded into the miRNA-associated RNA induced silencing complex (RISC or 
miRISC), including the mature single-stranded miRNA molecule and AGO proteins, where 
the mature miRNA could regulate gene expression, binding through partial complementarity 
to target messenger RNAs (mRNAs) and leading to translation inhibition or mRNA 
degradation, depending on the sequence complementarity between the miRNA and the target 
mRNA (reviewed by (Iorio and Croce 2012). Recent reports have tried to clarify the complex 
mechanisms regulating miRNA function on target mRNAs: microRNAs mainly recognize 
complementary sequences in the 3´ UTR of their target mRNAs, but recent studies have 
reported that they may also bind to the 5´ UTR or the open reading frame (Lytle, Yario et al. 
2007; Orom, Nielsen et al. 2008; Moretti, Thermann et al. 2010). Sites located in coding 
regions appear to be less robust than those in the 3’UTR (Gu, Jin et al. 2009) and, 
surprisingly, miRNAs can upregulate translation upon growth arrest conditions (Henke, 
Goergen et al. 2008; Orom, Nielsen et al. 2008; Vasudevan, Tong et al. 2008) (Figure 8). 
Moreover it has been evidenced that the mature form of microRNAs may also be localized in 
the nucleus (Hwang, Wentzel et al. 2007). 
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Figura 8. microRNAs biogenesis and function (Iorio and Croce 2012) 
 
miRNAs interact with their mRNA targets via base-pairing. The most important requirement 
is a contiguous and perfect Watson-Crick base-pairing of the seed region of the miRNA, the 
5’ nucleotides 2–8, guide for the base-pairing. However, functional miRNA sites that contain 
bulged nucleotides or mismatches in the seed region have also been identified as shown for 
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the Lin-41 mRNA targeted by let-7 miRNA in Caenorhabditis elegans (Vella et al., 2004). 
Moreover miRNA-mRNA duplexes containing mismatches and bulges in the central region 
(miRNA positions 10–12) could prevent endonucleolytic cleavage of mRNA. AU-rich 
sequence context and structural accessibility of the sites could improve their efficacy (Bartel 
2009). Multiple sites, for the same or different miRNAs, are required for effective repression, 
and when the sites are close to each other, they tend to act cooperatively (Grimson, Farh et al. 
2007).  
2.4.1 microRNAs and translation 
 
Several studies tried to clarify the mechanisms of protein synthesis suppression by 
microRNAs. These studies showed that miRNAs could inhibit translation of target mRNAs or 
facilitate their deadenylation and subsequent degradation. All miRNA-mRNA interactions 
seem to downregulate gene expression at post-trancriptional level, but the scale of regulation 
vary and depends on the specific miRNA-mRNA target combination. Whether this event is 
due by accessibility of the mRNA to miRNAs or by other factors is unknown (Maroney et al., 
2006). How do miRNAs regulate gene expression? Early analysis indicated that regulation 
was at the level of translation: the abundance of the regulated mRNA does not change, but the 
abundance of proteins encoded by these mRNAs was reduced (reviewed by (Maroney, Yu et 
al. 2006). The first question in clarifying the mechanism of translational repression by 
miRNAs is to determine whether miRNAs suppress the initiation of translation or act at the 
postinitiation stage. Lin-4 was discovered in C. elegans, and causes inhibition of translation of 
lin-14 without a reduction in mRNA levels or a shift in polysomes, leading to the conclusion 
that miRNAs could inhibit mRNA translation at the elongation step of the translation process 
(Olsen and Ambros 1999). In other experimental models several results denoted defects in the 
control of translation initiation and mRNA stability. miRNA-mediated repression of 
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translation initiation was observed in HeLa cells. Analysis of mRNA levels was unsuccessfull 
to detect pronounced degradation of mRNAs targeted by miRNA, demonstrating that 
translation was inhibited (Pillai, Bhattacharyya et al. 2005). Furthermore, let-7 targeted 
mRNAs shifted to lighter fractions of polysomal sucrose density gradients, an event that is 
indicative of repressed translation at the initiation step, caused by a defect in ribosome 
recruitment to the mRNA (Ding and Grosshans 2009). Moreover miRNAs which target 
mRNAs are present in the polysomes fraction, although the proteins encoded by those target 
mRNAs were not detectable. Since ribosomes already initiated translation of mRNAs present 
in the polysomes fraction, it was concluded that targets were silenced at the post-initiation 
stage. This model was supported by the observation that miRNAs silencing occurred in the 
absence of the 5′-cap structure (Petersen, Bordeleau et al. 2006). Several groups have reported 
that mRNAs that lack a functional 5’-cap structure, or that present a cap-independent 
translation, are refractory to a miRNA-mediated translational repression (Wang, Love et al. 
2006; Mathonnet, Fabian et al. 2007). All these studies concluded that the miRNA-mediated 
translation inhibition takes place at the initiation step and this is due to the interference with 
the cap recognition process. This is further supported by the findings that miRNAs failed to 
inhibit IRES-dependent translation or translation from ApppG-capped mRNAs. Moreover, 
several studies evidence that miRNAs translational repression is due to the inhibition of the 
80S complex assembly: miRNAs might affect 60S joining. eIF6 protein, associated with the 
60S ribosomal subunit, coimmunoprecipitated with the AGO2-Dicer-TRBP complex. 
Depletion of eIF6 from either human cells or C. elegans partially alleviated the inhibition of 
let-7 or lin-4 miRNA targets, leading to the conclusion that miRISC association with eIF6 
disrupts polysomes formation by inhibiting 80S complex assembly (Chendrimada, Finn et al. 
2007). However, the validity of these results was not confirmed because depletion of eIF6 
from Drosophyla cells had no striking effect on miRNA-mediated repression (Eulalio, 
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Huntzinger et al. 2008). The interaction of PABP with the eIF4G of the eIF4F complex led to 
an increase in cap-dependent translation of mRNAs (Kahvejian, Svitkin et al. 2005). Thus, 
miRNA-mediated mRNA deadenylation causes a reduction in translation initiation. The role 
of the poly(A) tail in miRNA-mediated translational repression is in open debate: both the 5’ 
cap and poly(A) tail were required for mRNA translational repression by a miRNA mimic in 
HeLa cells (Humphreys, Westman et al. 2005) but no substantial difference in the repression 
between capped poly(A)− and poly(A)+ mRNAs was noted by others (Meister, Landthaler et 
al. 2004). And again, numerous studies concluded that miRNAs could inhibit translation also 
at postinitiation steps. This conclusion was based from polysomal sedimentation analyses. 
Indeed the most used method to establish the step at which translation is blocked is the 
measurement of the location of mRNAs across a polysomal sucrose gradient. Recent studies 
in mammalian cells have displayed that miRNAs repressed mRNAs showed the same mRNA 
distribution pattern across poly-ribosomes compared with non-repressed mRNAs (Nottrott, 
Simard et al. 2006; Gu, Jin et al. 2009). Same results were reached by studies in C.Elegans 
(Seggerson, Tang et al. 2002). These results led to models of post-initiation inhibition of 
mRNA translation, including cotranslation protein degradation (Nottrott, Simard et al. 2006), 
increased premature termination (ribosomal dropoff) (Petersen, Bordeleau et al. 2006), and 
impaired elongation (Gu, Jin et al. 2009). Another method to distinguish initiation and post-
initiation inhibition relied on checking whether internal ribosome entry sequence (IRES)-
containing mRNAs were resistant to miRNA-mediated repression (Sonenberg and 
Hinnebusch 2009). Like the polysomal profile experiments, contradictory results were 
reported by different groups. Some studies demonstrated that IRES-initiated translation was 
still subject to miRNA-mediated repression, therefore excluding eIF4E-cap recognition as a 
potential target for miRNA function. Other studies concluded that microRNAs inhibit target 
mRNA translation at the initiation step (reviewed by Gu and Kay 2010).  
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2.4.2 microRNAs and cancer 
 
The first evidence of the involvement of microRNAs in human cancers derived from studies 
on chronic lymphocytic leukemia (CLL). Croce et al. discovered that a region of the 
chromosome 13 contains two microRNAs, miR-15a and miR-16-1, expressed in the same 
polycistronic RNA. This is the first evidence that microRNAs could be involved in the 
pathogenesis of cancers, and study of a large collection of CLLs  displayed that the 69% of 
CLLs showed knock-down of miR-16-1 and miR-15a (Iorio and Croce 2012).  They mapped 
all the known microRNA genes and found that many of them are placed in regions of the 
genome involved in chromosomal alterations, such as amplification or deletion (Calin, 
Sevignani et al. 2004). After these observations, all known microRNA genes have been 
mapped and several platforms have been developed. This results helpful to study the global 
expression of microRNA genes in normal and diseased tissues and establishes whether 
microRNA profiling could be used for tumor classification, diagnosis and prognosis (Calin 
and Croce 2006). microRNA profiles can distinguish not only between cancerous and normal 
tissues identifying also tissues of origin, but they can also discriminate different subtypes of a 
particular cancer or specific oncogenic abnormalities. Moreover, microRNA profiling can 
also predict disease outcome or response to therapy, such as miR-155 overexpression and let-
7a downregulation were able to predict poor disease outcome in lung cancer (Yanaihara, 
Caplen et al. 2006; Caramuta, Egyhazi et al. 2010).  Finally, but not less important, it is 
possible evaluating miRNA expression to predict the response to specific drugs since it might 
be useful for an accurate selection of patients potentially responsive to a specific therapy, as 
for miR-21 expression in the response of chemotherapy in pancreatic cancer (Giovannetti, 
Funel et al. 2010) and adenocarcinoma (Schetter, Leung et al. 2008). 
MicroRNA expression, like the expression of other cancer associated genes, can be altered by 
chromosomal amplification or deletion, promoter methylation, and transcription factor 
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activation. Many cancer cells have genetic alterations that are microRNA mechanism-
specific: altered target binding site, processing and post-transcriptional editing. Binding site 
variation in the 3’UTR of the target mRNA is a common feature of cancer cells (Ziebarth, 
Bhattacharya et al. 2012); mutations and single nucleotide polymorphisms (SNPs) have been 
identified, and also deletions of 3’UTRs during mRNA splicing in cancer cells, rendering 
mRNAs insensitive to regulation by microRNAs (Sun, Yan et al. 2009). Alterations in the 
microRNA processing machinery are reported in cancer cells. Mutations that impair the 
efficiency of the microRNA processing machinery have been identified, and they affect the 
levels of mature microRNAs in the cell, as for instance mutations in exportin-5 (XPO5)  lead 
to trapping of pre-microRNAs in the nucleus, preventing further microRNA processing 
(Melo, Moutinho et al. 2010).  
The complex program of cancer to elude the treatment relies on the communication between 
multiple cell types. The six main features of cancer progression are self-sufficiency in growth 
signals, apoptosis evasion, insensivity to anti-growth signals, angiogenesis, unlimited 
replicative potential, tissue invasion and metastasis (Hanahan and Weinberg 2000). 
Dysregulated microRNAs may function as tumor suppressors or as oncogenes in cancer by 
targeting each one of these processes (Figure 9).  
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Figure 9. microRNAs targeting the hallmarks of cancer (Iorio and Croce 2012) 
 
Gain-of-function approaches have shown that miRNAs act as tumor suppressors targeting 
oncoproteins with crucial roles in various cancer pathways, such as BCL2 targeted by miR-
15a–miR-16-1 (Cimmino, Calin et al. 2005), myeloid cell leukemia sequence 1 BCl-2-related, 
MCL1, targeted by miR-29 (Garzon, Heaphy et al. 2009), RAS and MYC regulated by let-7 
(Johnson, Grosshans et al. 2005; Sampson, Rong et al. 2007). To assess the biological effects 
of oncogenic miRNAs, frequently overexpressed in cancer cells, in vitro silencing, using 
antisense oligonucleotides, are helpful. This approach was used in breast cancer model (Iorio, 
Ferracin et al. 2005), colon cancer (Schetter, Leung et al. 2008) and glioblastomas (Ciafre, 
Galardi et al. 2005) in which miR-21 is overexpressed. Blocking miR-21 expression in these 
cell lines determined an increase on activation of caspases and apoptosis. Several miRNAs are 
reported showing oncogenic or tumor suppressor role, and among them, microRNAs in 
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clusters, which are expressed together and show functional cooperation, result of great 
importance. The oncogenic miR-17-92 microRNAs cluster induces lymphomagenesis in a B-
cell-specific transgenic mouse model (Sandhu, Fassan et al. 2013), and miR-19b, miR-20a, 
and miR-92 from this cluster, along with miR-26a and miR-223, promote T cell acute 
lymphoblastic leukemia (ALL) development in mouse models (Mavrakis, Van Der Meulen et 
al. 2011). Several studies reported that mice deficient for miR-17-92 cluster die after birth 
with a ventricular septal defect and lung hypoplasia (Ventura, Young et al. 2008). Instead, the 
deletion of the complete miR-17-92 cluster slows down Myc-induced oncogenesis (Mu, Han 
et al. 2009). In contrast, miR-155 overexpression in the lymphoid compartment was sufficient 
to induce cancer without any other cooperative mutation or Myc expression, suggesting that 
the dysregulation of a single miRNA can lead to malignancy (Iorio and Croce 2012). In 
addition to classical tumour suppressor or oncogene functions, miRNAs have been implicated 
also in cell migration and metastasis. The overexpression of miR-10b in metastatic breast 
cancer regulates cell invasion and migration, overexpressed miR-10b in non-metastatic breast 
cancer cells initiates invasion and metastasis. It was demonstrated that these effects are 
mediated by direct targeting of HOXD10 by miR-10b, improving the overexpression of the 
pro-metastatic gene RHOC (Tian, Luo et al. 2010). Other relevant examples are miR-126 and 
miR-335 which act as negative regulators of tumor invasion and metastasis in human breast 
and lung cancer (Tavazoie, Alarcon et al. 2008). It has been observed that primary tumors and 
metastasis from the same tissue show a similar pattern of microRNAs expression (Rosenfeld, 
Aharonov et al. 2008). miRNA profiling is a more accurate classifier than mRNA profiling, 
and thus has the potential to elucidate one of the most challenging issues in cancer diagnostic: 
the origin of metastasis of unknown primary tumors (Iorio and Croce 2012). Instead, miR-
34a, lost in several tumors and involved into the p53 mediated network (He, He et al. 2007), 
inhibits migration and invasion downregulating MET expression in human HCC cells (Li, Fu 
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et al. 2009). By the way, as part of their role in shaping the fate of a cell, microRNAs are also 
fundamental in the control of EMT. Some microRNAs, such as the miR-200 family and miR-
34a, are protectors of the epithelial phenotype, and their downregulation during EMT enhance 
targets as ZEB1 and ZEB2, mesenchymal specific (Hao, Zhang et al. 2014). And again, 
positive correlation of miR-138 and EMT has uncovered its role in driving the process 
through many targets including Vimentin, ZEB2 and epigenetic regulators such as EZH2 
(Liu, Wang et al. 2011). Similarly, it has been shown that miR-155 is able to repress TGFβ-
induced EMT, and depletion of this microRNA can suppress EMT in a mouse model (Kong, 
Yang et al. 2008). Currently, there are multiple clinical trials that are assessing the correlation 
between miRNAs expression and cancer diagnosis and prognosis. Due to the pleiotropic 
effects of miRNAs, they have been an attractive way for patients diagnosis evaluation and 
prognosis. Moreover, miRNAs, because of their size, are highly stable and resistant to 
RNAses and thus have a higher level of stability than mRNA (Price and Chen 2014). 
Expression profiles of many miRNAs derived from tumor tissues have been shown to be 
useful in prognosis and diagnosis of the patients. In this context miRNAs expression profiles 
can be used to classify various types of cancers, or poorly differentiated tumors, better that 
mRNA profile. For example, seven miRNAs, miR-15b, miR-23a, miR-133a, miR-150, miR-
197, miR-497 and miR-548b-5p, were decreased in the serum of patients with astrocytomas in 
advanced stage, and the miRNAs signature could  distinguish between normal and cancer 
patients (Yang, Wang et al. 2013). Furthermore, several studies have identified stable 
miRNAs in human serum or plasma and circulating miRNAs serve as diagnostic or 
prognostic indicators. Differential expression of circulating miRNAs has been showed in 
patients of many types of cancers, including breast cancer, multiple myeloma, prostate cancer, 
gastric cancer, colon cancer, pancreatic cancer, diffuse large B-cell lymphoma, lung cancer, 
squamous cell carcinoma and ovarian cancer (Price and Chen 2014).  
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Here we report a list of known microRNAs with biological role in Malignant Pleural 
Mesothelioma. 
 
 
Table 2. MicroRNAs with biological activity in MPM (modified from (Reid 2015) 
 
In conclusion, understanding how miRNAs regulate target genes in cancer initiation, 
progression, metastasis, relapse, and drug response and resistance is a notable point in the 
comprehension of the miRNAs related cancer biology. 
 
2.5 Protein Kinase C β and Enzastaurin 
 
Protein kinase C (PKC) is a family of phospholipid dependent serine/threonine kinases that 
function in numerous cell types, differ in their structure, cofactor requirement and substrates 
specificity. Based on their biochemical properties and activation characteristics, this protein 
family can be further classified into three subfamilies: conventional or classic PKC isozymes 
(cPKCs; 𝛼, 𝛽I, 𝛽II, and 𝛾), novel or nonclassic PKC isozymes (nPKCs; 𝛿, 𝜀, 𝜂, and 𝜃), and 
atypical PKC isozymes (aPKCs; 𝜁, 𝜄, and 𝜆). Conventional PKCs are calcium dependent and 
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activated by both phosphatidylserine (PS) and DAG, novel PKCs are calcium independent 
and regulated by DAG and PS, and finally, atypical PKCs are calcium-independent and do not 
require DAG for activation, although PS can regulate their activity (Griner and Kazanietz 
2007; Steinberg 2008). Phorbol esthers, such as phorbol 12-myristate 13-acetate (PMA) 
stimulates conventional (α, βI, βII, γ) and novel (δ, ε, η, θ) PKC by mimicking the activating 
ligand DAG. Typically, kinases exert their signaling activity either directly via a 
phosphorylation of the final effector protein or indirectly via modulation of intermediate 
factors. As part of a vast cellular system, PKCs are critically involved in the signaling of vital 
physiological responses, including inflammatory, autoimmune responses, tumor progression, 
and cardiovascular functions. They are cytosolic enzymes, although, once activated, they 
translocate to the cell membrane using the membrane anchoring receptors for activated C-
kinases (RACK) (reviewed by (Marengo, De Ciucis et al. 2011). The discovery of PKC, as 
the phorbol ester “receptor”, has led to a strong interest in the contribution of these kinases to 
tumorigenesis and tumor progression (Kikkawa, Takai et al. 1982). In cancer cells, PKC 
isozymes are involved in cell proliferation, survival, invasion, migration, apoptosis and 
angiogenesis, through their increased or decreased participation in various cellular signaling 
pathways. Particularly, PKCβ overexpression contributes in several ways to tumor formation 
and is involved in tumor host mechanisms such as inflammation and angiogenesis in breast 
cancer and in retinal tissue. Elevated expression of PKCβ seems to be an early event in colon 
cancer development and transgenic overexpression of PKCβII in the intestine induces hyper-
proliferation and an invasive phenotype in epithelial cells. In patients with diffuse large B-cell 
lymphoma, PKCβ is one of the most overexpressed genes while the loss of PKCβ expression 
has been observed in melanoma cell lines (Marengo, De Ciucis et al. 2011). 
Enzastaurin (LY317615.HCl) is an ATP-competitive and oral selective inhibitor of protein 
kinase C (PKC) β. It inhibits kinase activity by competing with ATP for the enzyme’s ATP 
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binding site. It was initially developed as a selective inhibitor of PKCβ, with a 50% inhibitory 
concentration (IC50) of 6 nmol/l. Enzastaurin also inhibits other PKC isoforms at higher 
concentrations (IC50 values calculated from a 10-point curve from filter-binding assays run at 
30 mmol/l ATP: PKCβ 0.006 mmol/l, PKCα 0.039 mmol/l, PKCγ 0.083 mmol/l, and PKCε 
0.110 mmol/l). Enzastaurin at low concentration, in a range of 1 to 4 μM, is able to suppress 
cell proliferation, and induce apoptosis, of various tumor cells such as colon carcinoma, 
glioblastoma, non–small cell lung cancer, breast cancer, leukemia, prostate cancer. In 
addition, Enzastaurin treatment can reduce the phosphorylation of glycogen synthase kinase 
(GSK)3βSer9, which has been linked to both PKCβ activity and AKT activity. Furthermore, 
Enzastaurin suppresses the phosphorylation of ribosomal protein S6 Ser240/244 and of AKT 
Thr308, suggesting that Enzastaurin also affects the AKT pathway (Figura 10). Initially 
Enzastaurin has been developed as an antiangiogenic agent, later it has been demonstrated 
that in xenograft models oral administration of enzastaurin at a dose of 75 mg/kg has a potent 
antitumor effects in multiple human cancer cell lines. (Graff, McNulty et al. 2005; Ma and 
Rosen 2007). 
 
Figure 10. Schematic of Enzastaurin activity 
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In clinical studies, Enzastaurin was well tolerated and has shown encouraging activity in a 
variety of tumors. Phase I studies showed that Enzastaurin is well tolerated at the 
recommended dose of 525 mg/day with few clinically significant grade 3 or 4 toxicities; 
evidence of early activity was seen with significant stable disease (Carducci, Musib et al. 
2006). A recent open-label, single-arm, phase II study of Enzastaurin investigated whether 
Enzastaurin has activity in patients with grade 1 or 2 follicular lymphoma and showed that 
Enzastaurin was well tolerated with mostly grade 1 or 2 toxicities (Schwartzberg, Hermann et 
al. 2014).  
Phase III study compared the efficacy and safety of Enzastaurin versus lomustine in patients 
with recurrent glioblastoma. Enzastaurin was well tolerated and had a better hematologic 
toxicity profile, but did not have superior efficacy compared with lomustine (Wick, Puduvalli 
et al. 2010). Moreover a phase III study of Enzastaurin in patients with high-risk diffuse large 
B cell lymphoma (DLBCL) showed that Enzastaurin did not improve disease-free survival, 
event-free survival, or overall survival in patients with high-risk DLBCL (Crump et al., 2013, 
http://hdl.handle.net/1854/LU-5792451). To date, exploring Enzastaurin as a monotherapy in 
the prevention of relapse in patients with DLBCL failed to show a statistically significant 
increase compared to placebo in disease-free survival.  
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2.6 Aim and main conclusions of the work 
 
Protein synthesis is a vital cellular process regulated during growth and development. Its 
deregulation can lead to cell apoptosis or disease. Molecular mechanisms and signaling 
pathways which control mRNA translation and the protein synthetic machinery are 
constituted by steps potentially involved in tumorigenesis, pointing them as novel druggable 
targets for cancer therapy. Translational control is rate-limiting in cancer growth and 
translation initiation step is emerging as an attractive therapeutic target. Drugs targeting the 
mTOR pathway, such as rapalogs, are used in cancer treatment, and explicate their action 
impairing eIF4F formation. Unfortunately not all cancer cells are sensitive to rapalogs. In this 
work we searched for initiation factors that are rate limiting for translation and controlled by 
growth factors activation, but not by mTOR. It has been shown that eukaryotic Initiation 
Factor 6 (eIF6) is a limiting factor in tumorigenesis, in vivo, regulating the availability of free 
60S subunit, and that inhibition of translation initiation is the earliest molecular event affected 
by miRNAs that play an important role in gene regulatory networks. eIF6 activity is regulated 
by Protein Kinase C isoform β  (PKCβII).  Most tumor cells overexpress both eIF6 and 
PKCβII. Here, we observed that Malignant Pleural Mesothelioma (MPM) shows high levels 
of phosphorylated eIF6 and that PKCβ inhibitor Enzastaurin (Ely-Lilly) induces eIF6 
dephosphorylation in time-dependent manner. Treatment of mesothelioma cells, with either 
Enzastaurin or shRNA for eIF6 reduces cell growth, in vitro, and impaired tumor growth and 
metastasis formation, in vivo. Furthermore, molecular analysis reveals that eIF6 manipulation 
affects the metabolic status of malignant mesothelioma cells, resulting in less glycolysis and 
less ATP content after depletion of eIF6 or Enzastaurin treatment. In addition, since miRNAs 
may inhibit the translation of target mRNAs at the initiation stage of protein synthesis or at 
the postinitiation phase, we performed a sucrose density gradient analysis of MPM cells 
allowing mRNAs to be separated, based on the number of polysomes associated. To identify 
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the localization of miRNAs in RNA subpopulations, we analyzed miRNAs distribution both 
in monosomes and active polysomes and we found that the miRNA signature was 
characterized also by differential miRNAs distribution. In particular, only some miRNAs 
were expressed in the polysomal pool with variability in miRNAs occupancy, indicating that 
some miRNAs can repress translation, while others cannot.  
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3. MATERIALS AND METHODS 
 
3.1 Mice 
 
All experiments involving mice were performed in accordance with italian national 
regulations. Experimental protocols were reviewed by local Institutional Animal Care and 
Use Committees (IACUC form sk481). Eight-week old immunocompromised NOD-SCID 
mice (Charles River Laboratories) were used for detecting tumor growth after intraperitoneal 
(i.p.) injection of REN cells, as indicated. 
3.2 Cell lines and lentiviral vectors 
 
For this study we used different MPM cell lines: REN cells for Epithelioid subtype, MM98 
for Sarcomatous subtype and MSTO-211H for Biphasic subtype. Met-5A (ATCC® CRL--
9444™) are SV40 immortalized non-tumorigenic mesothelial cells. REN and MM98 cells 
were grown in DMEM (Lonza), MSTO-211H were grown in RPMI1640 (Lonza) and Met-5A 
cells in Medium 199 (Life Tech). All media were supplemented with 10% FBS (Fetal Bovine 
Serum) and 1% penicillin, streptomycin, L-glutamine, and all cells were maintained at 37°C 
and 5% CO2. For Western Blotting analysis, normal human primary mesothelial cells were 
used as Non-tumoral control. Cells were purchased from Cambridge Bioscience (Cambridge, 
UK) and maintained according to manufacturer instructions, up to 3 passages. Densitometric 
analysis was performed by ImageJ software. 
MPM cells were stably infected with either one constitutive lentiviral vector carrying 
scramble ShRNA, used as control, or one carrying eIF6 ShRNA. Lentiviral vectors, pGIPZ 
Lentiviral ShRNA, were provided by Open Biosystem. Specifically, mature antisense 
sequences of constitutive shRNA of eIF6 were: 5'-AGCTTCCTACTAGCACCTG-3' 
(V3LMM_421640; GIPZ eIF6 shRNA: RMM4532-EG16418). After lentiviral infection, REN 
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cells were selected with puromycin (1µg/ml) for 48 hours, expanded and treated with 
Enzastaurin as specifically described. 
 
3.3 Antibodies and reagents 
 
The following antibodies were used: rabbit polyclonal antibodies against eIF6, rpS6, 
phospho-rpS6 (Ser240/244), total 4EBP1 (Cell Signaling), P-PKCII (Cell Signaling); goat 
polyclonal anti-rpL28 and anti-PKCII (Santa Cruz) rabbit polyclonal anti-VEGFA (Abcam); 
mouse monoclonal antibodies against -Actin (Sigma), PKC (BD-Bioscience) RACK1 IgM 
(BD Transduction Laboratories). Biotin was obtained from Pierce, EuroClone (EZ-LINK 
NHS-LC-BIOTIN). Lambda Protein Phosphatase (Lambda PP) was provided by NEB. 
Enzastaurin was provided by Eli Lilly and Company (Indianapolis, USA). eIF6 recombinant 
protein was produced in E. Coli by simultaneous co-expression with chaperones, followed by 
affinity chromatography and size exclusion chromatography (SEC; GE Healthcare), according 
to (Pesce, Minici et al. 2015).  
3.4 RNA extraction and real time RT-PCR 
 
Total RNA was extracted with TRIzol reagent (Invitrogen). After treatment of total RNA with 
RQ1 RNase-free DNase (Promega), reverse transcription was performed with MMLV reverse 
transcriptase enzyme (Promega) according to the manufacturer’s instructions. Reverse 
transcribed complementary DNA (100 ng) was amplified with the appropriate primers. 
Taqman probes specific for eIF6 (Hs00158272_m1) and 18S rRNA as an internal standard, 
were used. Target mRNA quantification by quantitative reverse-transcriptase PCR using 
ΔΔCt-method using Taqman Universal PCR Master Mix (4304437; Life Technologies) was 
performed on an ABIPRISM 7900HT Sequence Detection System (Applied Biosystems). 
Results are represented as means ± SD of at least three independent experiments. 
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For total, subpolysomal and polysomal RNA extractions from sucrose gradient aliquotes, the 
sucrose fractions were divided in two. The pulled fractions were used for subpolysomal and 
light and heavy polysomal RNA. Afterward, samples were incubated with proteinase K and 
SDS 1% for 1 h at 37°C. RNA was extracted by phenol/chloroform/isoamyilic acid method. 
The same defined amounts of synthehtic RNA spike-ins (osa-miR-414, ath-miR-159a, cel-
miR-248) are added to all samples during preparation, to normalize the measurement of the 
RNA samples. 
3.5 Cell proliferation, cell cycle and cell death analysis 
 
Proliferation rate of MPM cells was analyzed by MTT test: briefly, cells were plated in 96 
wells plates at different concentration, and assayed after 24, 48 and 72 hours. MTT (3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) was added and left on cells for 3 
hours at 37° C and 5% CO2. The resulting intracellular purple formazan was solubilized with 
SDS and quantified by spectrophotometer at λ= 550/650 nm. Cell cycle analysis was 
performed on G1 synchronized REN cells. Cells were starved in DMEM without FBS for 12 
hours, and then in PBS plus 0,5 mM MgCl2, 10 mM D-Glucose, 1mM CaCl2 for 3 hours. At 
the indicated time points, cells were fixed, stained with propidium iodide (PI) and acquired on 
a BD FACS CANTO II flow cytometer. Cell cycle analysis was performed using the FCS 
Express software (BD). Cell death detection was performed using APC-Annexin V 
(BioLegend). Each experiment was done at least in triplicate. 
3.6 Polysomal profile 
 
Growing cells were lysed using a glass douncer in 50 mM Tris HCl pH 7.8, 240 mM KCl, 10 
mM MgSO4, 5mM DTT, 250 mM sucrose, 2% Triton X-100, 90 μg/ml cicloheximide, 30U/ml 
RNasin. After centrifugation at 39000 r.p.m. for 3 hours at 4 °C, the equivalent of two-
hundred micrograms of RNA was loaded on a 15-55% sucrose gradient dissolved in 25 mM 
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Tris HCl pH 7.4, 25 mM NaCl, 5 mM MgCl2, 1 mM DTT and spun at 260.000 g for 3h30min 
with SW41Ti swing rotor (Beckman Coulter). The gradient was then analyzed by continuous 
flow absorbance at 254 nm, recorded by BioLogic LP software (BioRad). Peaks for 40S, 60S, 
80S and polysomes were quantified. For dissociation studies, total extracts of REN cells were 
incubated 2 minutes at 37 °C, with 5µg of recombinant eIF6  protein or matched controls 
(PBS; denatured protein), and separated on a 7-45% sucrose gradient.  Extracts containing up 
to 200 micrograms of RNA were loaded on a 7–45% (w/v) sucrose gradient containing 50 
mM Tris-acetate pH 7.5, 50 mM NH4Cl, 12 mM MgCl2 and 1 mM DTT, and centrifuged in a 
Beckman SW41 Ti rotor for 3h30min at 260.000 g.  The gradient was analyzed as above. In 
addition, individual fractions were collected. Fractions were precipitated with 10% 
trichloroacetic acid (TCA), separated on SDS-PAGE and analyzed by Western blot.  
For microRNAs profiling on polysomal profile of REN cell, they were lysed using a glass 
douncer in 50 mM Tris HCl pH 7.8, 240 mM KCl, 10 mM MgSO4, 5mM DTT, 250 mM 
sucrose, 2% Triton X-100, 90 μg/ml cicloheximide, 30U/ml RNasin ± 30mM EDTA. 
Following clearing, RNA was loaded on a 10-50% sucrose gradient dissolved in 25 mM Tris 
HCl pH 7.4, 25 mM NaCl, 5 mM MgCl2, 1 mM DTT ± 30mM EDTA, and spun at 260.000 g 
for 3h30min with SW41Ti swing rotor (Beckman Coulter). The gradient was then analyzed by 
continuous flow absorbance at 254 nm, recorded by BioLogic LP software (BioRad). Peaks 
for 40S, 60S, 80S and polysomes were quantified. Fractions of 1 ml were collected. 
3.7 Datamining 
 
Datasets were retrieved by GEO databases. The affy package was then used to carry out RMA 
based normalization. Quantitation of target genes was performed by setting expression 
thresholds at upper one/third. Calculation was performed as follows: original set of 
microarray data was retrieved from GSE2549. The dataset contains 54 MMP patients. 
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Samples without follow-up survival were discarded, obtaining 42 patients. Expression data on 
eIF6 and PRKCB were retrieved. Retrieved values ranged for eIF6 from 106 (min) to 468 
(max), and for PRKCB from 62 (min) to 403 (max). Assuming that eIF6 
hyperphosphorylation and overexpression were linked, we calculated the combined 
expression by multiplying the eIF6 x PRKCB values. Samples which gave a result in the first 
quartile of combined expression (practically with values above 1.5 fold the average 
expression of eIF6 and PRKCB) were compared to the others with the null hypothesis that 
combined eIF6-PRKCB expression had no effect on survival. Statistical analysis was 
performed by a paired t-test.   
3.8 Immunohistochemistry 
 
Immunohistochemical and histological analysis were performed on paraffine-embedded 
human mesothelioma tissues (provided by Hospital Dall'Angelo, Pathology, Venice, Italy). 
Immunoistochemistry (IHC) for eIF6 and calretinin were done using the Vectastain Elite ABC 
kit (Vector), as previously described (Sanvito, Vivoli et al. 2000; Gandin, Miluzio et al. 2008; 
Carbone, Ly et al. 2012). Some sections were counterstained with Hematoxylin-Eosin (H&E). 
3.9 Two-dimensional (2D) gel electrophoresis 
 
Protein extracts of REN, Met-5A and tumor samples, in all described conditions were 
examined in 2D gel electrophoresis. Samples were lysed in SDS-free RIPA buffer and 
proteins were precipitated with 10% TCA. Pellets were resuspended in 2-D buffer (7 M Urea, 
2 M Thiourea, 50 mM DTT and 4% CHAPS) and 100 μg of proteins were isoelectrofocused. 
The first dimension was performed on Ready Strip IPG (pH 3.9–5.1; Biorad). For the 
reduction/alkylation step, the strips were incubated with re-equlibration buffer (50 mM Tris-
HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, bromophenol blue) plus 10 mg/ml of DTT 
and re-equilibration buffer plus 45 mg/ml of iodoacetamide, respectively. Then, the strips 
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were subjected to SDS/PAGE for the second dimension. Proteins were transferred on PVDF 
membrane and subsequently incubated with eIF6 monoclonal antibodies. The signal was 
detected with an anti-mouse secondary antibody and ECL substrate kit (GE Healthcare). Each 
experimental sample was run at least twice, and at least three different biological replicates 
were analyzed. 
3.10 Measurements of lactate secretion and ATP content 
 
REN cells were plated at 2x105 cells/well in 12-well dishes in high-glucose medium for 24 hr. 
Cells were switched to serum-free high-glucose (4,5 g/L)/high insulin (100 nM) medium for 4 
hr. Lactate secreted into the medium was measured using a fluorogenic assay, Lactate Assay 
Kit (Biovision). Average of fluorescent intensity was calculated for each condition replicates. 
Values were normalized to protein content obtained from the same wells. For ATP 
measurements, cells were lysed in ice-cold ATP buffer (20 mM Tris, pH 7.5, 0.5% Nonidet P-
40, 25 mM NaCl, 2.5 mM EDTA) for 5 min. Lysates were centrifuged at 13000 g for 30 min.  
Proteins were quantitated by BCA analysis. Luminometric determination of ATP was assayed 
using the ATP-determination kit (Molecular Probes). 
3.11 microRNAs profiling 
 
RNAs were processed with the nanoString nCounter system (nanoString, Seattle,Washington, 
USA) in the Nucleic Acid Shared Resource of The Ohio State University. By probes 
hybridization reaction, the miRNA panel can detect 699 endogenous miRNAs (with 654 
probes), 5 housekeeping transcripts and 3 Spike-in RNA, small RNA molecules used as 
control. After hybridization, probes in excess are removed and samples are immobilized on a 
nCounter Cartridge. The cartridge is placed in a Digital Analyzer instrument and data are 
collected. 
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3.12 Statistical analysis 
 
Each experiment was repeated at least three times, as biological replicates; means and 
standard deviations between different experiments were calculated. Statistical p-values 
obtained by Student t-test were indicated: three asterisks *** for p-values less than 0.001, two 
asterisks ** for p-values less than 0.01 and one asterisk * for p-values less than 0.05.  
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4. RESULTS 
 
4.1 eIF6 and Malignant Pleural Mesothelioma 
 
4.1.1 eIF6 is a marker of aggressive Malignant Pleural Mesothelioma (MPM) 
 
To study whether eIF6 protein was expressed in malignant pleural mesothelioma (MPM), we 
performed an immunohistochemistry staining on 24 human MPM samples, using an anti-eIF6 
polyclonal antibody (Biffo, Sanvito et al. 1997). Of these, 19 were epithelial, 3 sarcomatous, 
and 2 biphasic, as reported in Table 1.  
    Patients           Age(years)              Therapy                  Survival(months)        Histotype 
Number/Sex   
 
1. Male                           55                        PI+CT+RT                           11                          EP 
2. Male                           58                        PPE+CT+RT                        9                           EP 
3. Male                           59                        TP+CT+RT                         42                           EP 
4. Male                           60                        PT                                       15                           EP 
5. Male                           60                        CT+RT                                42                           EP 
6. Male                           63                        TP+CT+RT                         38                           EP 
7. Male                           64                        PPE                                      3                            S 
8. Male                           65                        PPE+CT                             13                           EP 
9. Male                           67                        PPE+CT                               9                           EP  
10. Male                         68                        PPE+CT                             10                           EP 
11. Male                         68                        PPE+CT                               9                           EP 
12. Male                         69                        PI+CT+RT                          16                           EP 
13. Male                         70                        TP+CT+RT                         38                           EP 
14. Male                         71                        TP+CT+RT                         25                            B 
15. Male                         71                        TP+CT                                17                           EP 
16. Male                         71                        TP+CT+RT                         25                            B  
17. Male                         72                        PPE                                      8                           EP 
18. Male                         75                        TP+CT                                  4                           EP  
19. Male                         76                        CT+RT                                13                           EP 
20. Male                         76                        TP+CT                                14                           EP                                 
21. Male                         80                        NO                                        3                            S 
 
 
22. Female                     68                        CT                                        6                            S 
23. Female                     75                        CT+RT                                 8                           EP 
24. Female                     77                        TP+CT                               26                           EP 
 
 
Histotypes:     EP: Epithelioid      B: Biphasic       S: Sarcomatous 
 
Therapy:         TP: Total Pleurectomy     PPE: Pleuropneumonectomy  CT: Chemotherapy 
                        RT: Radiotherapy 
                      
Table 1. Human Malignant Pleural Mesothelioma Cases used for Immunohystochemistry 
analysis. 
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Representative stainings of epithelioid and biphasic histotypes of MPM are shown in Figure 
11. Human epithelioid biopsies showed widespread mesothelioma infiltration that presented, 
with different prevalence, epithelial and connective components. Tumor components were 
characterized by islands or tubular formations. Biphasic histotypes showed both spindle-
shaped cells, typical of sarcomatoid subtype, and epithelial areas. In all analyzed cases, eIF6 
was expressed at high levels both in the nucleoli (black arrows) and in the cytoplasm of MPM 
cells. Nucleoli were enlarged, suggesting abnormal ribosome biogenesis. By using calretinin 
as a diagnostic marker for MPM, we confirmed that eIF6 overexpression was limited to tumor 
cells. Conversely, both eIF6 and calretinin are less expressed in non-tumoral pleural biopsies 
(Fig. 11). 
 
Figure 11. eIF6 is expressed at high levels in Malignant Pleural Mesothelioma tissues. IHC 
stainings on representative human non-tumoral samples and on biopsies of epithelial and biphasic 
malignant pleural mesothelioma biopsies show that eIF6, marked in brown, is highly expressed both in 
the nucleoli, as indicated by black arrows, and in the cytoplasm of tumor cells; we used Calretinin as a 
positive marker of MPM tumors.  
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Next, we evaluated both eIF6 expression and phosphorylation on human MPM epithelial 
tumors. First, we confirmed by Western Blot analysis that eIF6 overexpression is a 
constitutive feature of MPM (Fig. 12 A). Second, 2-D electrophoresis on a pool of three 
tumoral samples displayed 3 well-focused spots compatible with eIF6 phosphorylation sites. 
Tumors treated with phosphatase showed a single focused spot (Fig. 12 B).  
 
 
Figure 12. eIF6 is overexpressed and hyperphosphorylated in MPM tumors.  A) Western Blot 
analysis of different human biopsies of malignant pleural mesothelioma, indicated as A-E, displays 
that eIF6 protein levels are higher in tumor samples compared to non tumoral ones. We used actin as 
loading control. B) Bidimensional electrophoresis performed on a pool of three tumoral extracts 
indicates that eIF6 is hyperphosphorylated in MPM cells. We can see the phosphorylation sites of the 
protein as focused spots. Predicted eIF6 isoelectric points are indicated. The same samples, treated 
with PPase as control, show a single focused spots. 
 
We data-mined eIF6 mRNA levels from MPM microarray studies. Data showed that 35/42 
MPM patient datasets expressed higher levels of eIF6 mRNA in tumor samples. However, no 
relationship between eIF6 mRNA levels at time of analysis and survival was observed. eIF6 
can be phosphorylated by the RAS/PKC pathway. We data-mined on mesothelioma datasets 
the expression of PKC(PRKCB), the favoured RACK1 partner. Combined expression of 
PRKCB and eIF6 was then used to evaluate survival. Strikingly, high eIF6/high PRKCB 
expression correlated with lower survival, p ≤ 0.005 (Fig. 13). In conclusion, the combination 
of eIF6 expression and phosphorylation correlates with negative survival, raising the question 
whether its inhibition may be beneficial. 
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Figure 13. High co-expression of eIF6 and PKCβ is associated to lower survival of MPM 
patients. We used data of PRKCB and eIF6 expression derived bu mesothelioma datasets to evaluate 
survival of MPM patients. High eIF6/high PKCβ expression correlates with lower survival. 
 
 
 
4.1.2 eIF6 hyperphosphorylation in REN, a MPM cell line 
 
We analyzed the expression and phosphorylation of eIF6 in the epithelial MPM cell line, 
REN, and compared it to the expression of eIF6 in non-tumorigenic Met-5A mesothelial cells. 
We observed that REN cells show an increase of both eIF6 protein levels (Fig. 14A) and of 
mRNA levels (Fig. 14B), indicating that it is highly expressed in MPM cells. In Fig 14C we 
analyze the phosphorylation pattern of REN and MET-5A cells, showing that MPM cells 
display more focused spots than mesothelial cell line. This means that eIF6 is 
hyperphosphorylated in REN cells, but not in mesothelial MET-5A cells.  
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Figure 14. eIF6 is overexpressed and hyperphosphorylated in epithelioid REN cells. A) Western 
Blot analysis shows that eIF6 is overexpressed in REN cells compared to non-tumorigenic Met-5A 
cells. B) Real-Time PCR confirms that eIF6 mRNA levels are increased in REN cells. C) 
Representative 2-D gel electrophoresis on REN and Met-5A cells shows that REN cells display more 
focused spots than the MET-5A cells, therefore eIF6 is hypershosphorylated in REN cells, but not in 
non tumorigenic cells.  
 
Phosphorylation of eIF6 occurs downstream of RACK1/PKC activation. PKC is the 
preferential partner of RACK1 (Ceci, Gaviraghi et al. 2003). Enzastaurin is a specific 
PKCinhibitor that has been used in clinical trials for treating B-cell malignancies, i.e. 
(Schwartzberg, Hermann et al. 2014). Enzastaurin (1µM) was administered to REN cells, in 
growing conditions. Cells were lysed at 24 hours, 48 hours and 72 hours post-treatment and 
the degree of eIF6 phosphorylation was analyzed by 2-D electrophoresis, followed by 
Western Blot analysis. Growing REN cells showed 4 well-focused spots compatible with eIF6 
phosphorylation state. Cells treated with 1µM Enzastaurin, up to 48 hours, showed 3 spots 
compatible with 1-2 phosphate groups. Long-term treatment (72 hours) of Enzastaurin 
augmented dephosphorylation of eIF6. Finally, cell lysates treated with phosphatase showed a 
single focused spot (Fig. 15A). Enzastaurin did not affect the stability of both eIF6 and PKC, 
but the latters are more expressed in REN cells compared to non-tumoral Met-5A cells (Fig. 
15C). It was recently reported that Enzastaurin affects the phosphorylation of the downstream 
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target of mTORc1 kinase, 4E-BP1, the main mediator of cap-dependent translation 
(Dumstorf, Konicek et al. 2010). However, in MPM both 4E-BP1 and rpS6 were 
phosphorylated in the presence of Enzastaurin (Fig. 15B), indicating that mTORc1 kinase is 
not inhibited by Enzastaurin and remains activated. 
 
 
 
Figure 15. eIF6 hyperphosphorylation in REN cells is sensitive to Enzastaurin treatment, not 
affecting mTOR pathway. A) Representative 2-D gel electrophoresis on REN cells treated with 1µM 
Enzastaurin for 24, 48 and 72 hours shows that eIF6 phosphorylation is sensitive to Enzastaurin 
treatment, in a time dependent manner. Lambda PPase is used as positive control of unphosphorylation 
state. B) Representative Western Blot analysis on REN cells treated with Enzastaurin at different time 
points indicates that mTORc1 kinase is activated: phosphorylation of rpS6 and 4E-BP1 are equivalent 
in control cells and upon drug treatment. PP242 treatment is used as control of mTORc1 inactivation. 
C) Western Blot analysis shows that eIF6 and PKCβ are overexpressed in REN cells compared to non 
tumoral Met-5A cells. Proteins levels are similar upon Enzastaurin treatment in all considered times. 
 
In conclusion, the MPM cell line REN has eIF6 PKC-dependent hyperphosphorylation and 
can be used to investigate the effects of eIF6 depletion and dephosphorylation. 
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4.1.3 eIF6 antiassociation activity is important for recycling inactive 80S 
 
eIF6 acts in the regulation of translation initiation. We performed a methionine incorporation 
assay and polysomal profiles on REN cells, to analyze whether eIF6 levels can affect 
initiation. REN cells were previously infected with lentivirus carrying siRNAscramble as an 
internal control and siRNA eIF6. We showed a representative experiment performed on REN 
cells with either normal eIF6 protein levels (control and ShRNA Scramble), or reduced ones 
(ShRNA eIF6). Western Blot analysis displays that eIF6 protein expression has been reduced 
of ~ 80%, as indicated in Fig.16A. eIF6 depletion caused a significant reduction of newly 
synthesized proteins, as shown in Fig. 16B, indicating that eIF6 protein level is able to affect 
protein synthesis. Moreover, as we can see in fig 16C, polysomal profile indicate that the 
reduction of eIF6 protein level led to a slight decrease of polysomes accompanied by 80S 
accumulation. This means that eIF6 level is able to affect translation, particulatly the initiation 
step. Ratios of 80S/polysomes in each graph are also indicated. 
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Figure 16. eIF6 depletion modulates protein synthesis in REN cells. A) Western Blot analysis on 
REN cells for eIF6 expression in all considered conditions show a reduction of ~80% of protein level. 
Data are normalized on -Actin. B) Mean of three independent Methionine incorporation experiments 
indicates that eIF6 reduction affects protein synthesis of REN cells. C) Polysomal profiles show that 
partial depletion of eIF6 causes 80S accumulation and reduced translation. 
 
Since Enzastaurin modulated eIF6 activity, we performed polysomal profiles and Methionine 
incorporation assay on REN cells, after treatment with the drug. We observed that Enzastaurin 
caused an increase of 80S peak in REN cells, but not in Met-5A (Fig. 17A), indicating a 
defect in the initiation of translation. We showed also that Enzastaurin determines a severe 
reduced protein synthesis (Fig. 17B), as we described also for eIF6 partial depletion. 
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Figure17. Enzastaurin impairs translation and causes a reduction of protein synthesis. A)  
Representative polysomal profile on REN and Met-5A cells shows that Enzastaurin causes 80S 
accumulation and therefore reduced translation. B) Protein synthesis is significantly impaired upon 
Enzastaurin treatment, showed by reduction of methionine incorporation after drug treatment. 
 
The limited amount of translational inhibition by eIF6 depletion, in vivo, is in line with the 
fact that eIF6 is not strictly necessary for translation, but is rate-limiting for oncogene-induced 
protein synthesis (Miluzio, Beugnet et al. 2011). Next, we analysed in an ex-vivo experiment 
the requirement for eIF6 on 80S cancer ribosomes, examining the effect of the recombinant 
eIF6 on protein synthesis, by translational profile approach. Therefore, we prepared 
polysomes extracts from REN cells and added recombinant eIF6 protein. Figure 18 shows that 
eIF6 addition can dissociate inactive 80S, as shown by the drop in the 80S peak and the 
simultaneous increase of free 60S, evidenced by the accumulation of 60S peak. We recovered 
all fractions derived from polysomal profiles in order to analyze proteins distribution by 
Western Blotting. We show that exogenous eIF6 was detected both on soluble and 60S 
fractions, but not in polysomal fractions, consistent with the dissociation data.   
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Figure 18. eIF6 causes the dissociation of inactive 80S. We added 5 µg of recombinant biotinylated 
eIF6 protein to polysomes extracts of REN cells and we show that exogenous eIF6 determines the 
dissociation of inactive 80S, in MPM cell line. Western Blot analysis on recovered fractions derived 
from polysomal profiles exhibits the distribution of indicated proteins, evidencing that exogenous eIF6 
is present in soluble and 60S fractions. 
 
 
Taken together our data indicate that eIF6 activity in cancer cells is necessary for keeping 
ribosomes dissociated, and for initiating new protein synthesis. We wondered whether this 
activity is important for tumor growth. 
 
4.1.4 eIF6 reduction and dephosphorylation slow cell growth in cultured cells 
 
Established that eIF6 is hyperexpressed and hyperphosphorylated in MPM and in the REN 
cell line, we asked whether its depletion or dephosphorylation affected growth. We analysed 
MPM cells growth at 24, 48 and 72 hours after plating and upon eIF6 depletion (Fig. 19). 
MTT assay revealed that the proliferation rate of eIF6 depleted cells was slightly reduced 
compared to the control, in vitro.  
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Figure 19. Partial depletion of eIF6 affects proliferation of MPM cell lines. We analysed the 
proliferation rate of 3 different MPM cell lines, representative of MPM histhological subtypes, after 
transduction with shRNA scramble and shRNA eIF6 vectors. MTT assay reveals that eIF6 depletion 
impairs proliferation in all cell lines considered, REN (epithelioid), MM98 (sarcomatous) and MSTO-
211H (biphasic). 
 
In parallel, we performed a MTT Assay on REN cells, treated with 1µM, 5µM and 10µM of 
Enzastaurin and we measured the proliferation rate at the indicated time points (Fig. 20A). 
Enzastaurin reduced REN growth, indicating its cytostatic effect. The effect was more evident 
in low-serum conditions. eIF6 protein levels were very similar at all time points upon 
Enzastaurin treatment at the indicated concentrations (Fig. 20B).  
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Figure 20. Enzastaurin treatment impairs proliferation of REN cells. A) MTT assay on REN cells 
treated with 1µM, 5µM and 10 µM of Enzastaurin shows that high doses and long-term treatment with 
Enzastaurin reduce REN cell growth, indicating its cytostatic effect that becomes stronger under serum 
deprivation. B) Western Blot analysis reveals that Enzastaurin does not affect eIF6 protein levels even 
at high concentrations. 
 
 
Furthermore, we performed FACS analysis on synchronous REN cells, with normal or 
depleted eIF6 protein levels, and/or treated with 1μM Enzastaurin. Data confirmed that eIF6 
reduction impaired G1/S progression and caused a reduced number of cycling cells in G2/M 
phase. Similar results were obtained with Enzastaurin treatment (Fig. 21). 
 
Figure 21. eIF6 depletion and Enzastaurin treatment impairs G1/S progression in REN cells.   
Cell cycle analysis of synchronous REN cells, with normal or depleted eIF6 protein levels, and treated 
with 1μM Enzastaurin reveals that eIF6 reduction impairs G1/S progression in synchronised REN cells 
and causes a reduced number of cycling cells in G2/M phase, at considered time points. 
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Finally, we quantitated the apoptotic rate of all these cells after 72 hours of treatment: we 
found that the percentage of cell death was similar in all considered condition (Fig. 22A, B) 
 
 
 
 
 
 
 
Figure 22. Depletion of eIF6 and Enzastaurin treatment do not affect apoptosis rate in REN 
cells.  A) We analyze apoptotic rate of REN cells after transduction with siRNA scramble and siRNA 
eIF6 vectors. FACS analysis shows that the apoptotic rate is similar in all considered conditions. We 
used Staurosporin as positive control. B) Analysis of cell cycle of REN cells with normal and reduced 
level of eIF6 protein treated with Enzastaurin displays similar apoptotic rate in all evidenced 
conditions. 
. 
 
In conclusion, both shRNA for eIF6 or Enzastaurin treatment slightly reduce proliferation in 
cultured REN cells, in vitro.  
 
4.1.5 eIF6 depletion and Enzastaurin administration have an antitumoral 
effect, in vivo 
 
Then, we addressed the role of eIF6 activity and Enzastaurin, in vivo. We developed a murine 
MPM model by injecting REN cells into immunocompromised NOD-SCID mice. We injected 
i.p. 10 millions cells/mouse with either wt eIF6 or eIF6 depleted cells. A group of control 
mice was treated with Enzastaurin:  administration (75 mg/Kg) was performed by gavage 
twice/daily, starting at day 7 after injection and suspending it after 5 weeks. Mice were 
sacrificed 60 days after cells injection and tumor mass was analyzed. By autopsy, we 
measured the weight of total body, tumor mass, spleen and diaphragm and we scored for 
A B 
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developed metastasis and hemorrhage (Fig. 23). Mice injected with REN cells depleted of 
eIF6 showed reduced tumor mass weight, indicating that the amount of eIF6 is a limiting 
factor for cellular growth, in vivo. These mice also revealed less metastasis, since the 
diaphragm weight was reduced. Enzastaurin administration provided also a protective effect 
against tumor growth: indeed, tumor mass was strongly reduced, metastases were limited to 
diaphragm and hemorrhage was mild. 
 
Figure 23. eIF6 depletion and Enzastaurin administration reduce tumor growth, in vivo. REN 
cells with either wt or depleted eIF6 protein are injected (i.p.) in NOD-SCID mice. A cohort 
of control mice were treated with Enzastaurin (75mg/kg) twice daily for 5 weeks. Mice were 
sacrified two months after tumoral cells injection. We can see that eIF6 depletion and 
Enzastaurin administration reduce tumor masses weight and diaphragm metastasis 
 
 
Both Enzastaurin-treated tumors and shRNA eIF6 tumors recovered from NOD-SCID mice 
showed less CD31 and VEGFA-positive cells, indicating reduced angiogenesis and close 
correlation with diminished solid tumor growth and metastasis (Fig.24).  
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Figure 24. Reduced expression of eIF6 and Enzastaurin administration cause a decrease of 
angiogenesis. IHC stainings of tumors recovered from NOD-SCID mice. Tissue morphology is 
evidenced with Hematoxylin and Eosin staining; eIF6 is overexpressed both in the nucleoli 
(black arrows) and in the cytosol of tumoral cells; staining for CD31 (black arrows) reveals 
positive vessels; neo-angiogenesis is diminished both in eIF6 depleted conditions and upon 
drug administration. Scale bar is indicated. 
 
In addition, we recently found that VEGFs genes are translationally controlled by eIF6 levels: 
we observed that 50% of eIF6 protein significantly reduces VEGF and VEGF expression. 
(Brina, Miluzio et al. 2015). These findings may be in agreement with the protective role of 
eIF6 depletion and/or inactivation by Enzastaurin in neo-angiogenesis and metastasis 
development.  
Taken together, these data suggest that both inhibition of eIF6 expression and eIF6 
phosphorylation is effective in vivo, or that eIF6 is potentially targetable by Enzaustarin.  
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4.1.6 eIF6 depletion and Enzastaurin cause metabolic changes of cancer cells 
 
The protective role of reduced eIF6 and Enzastaurin administration in vivo, compared to the 
modest effects on cell growth in vitro raises the question of whether this effect could be 
linked to metabolic changes of tumoral REN cells. This selective effect would be consistent 
with the limited effect of eIF6 depletion on basal translation. A screening for eIF6-regulated 
mRNAs showed several transcription factors involved in metabolism (Brina, Miluzio et al. 
2015). Here, we show that acute depletion of eIF6 by lentiviral ShRNA on REN cells, and 
Enzastaurin treatment led to a reduction of lactate secretion, an index of glycolytic flux, that 
became significant after 72 hours from lentiviral infection and drug treatment (Fig. 25A). In 
both cases ATP production was significantly reduced in each considered time (Fig. 25B).  
 
Figure 25 eIF6 depletion and Enzastaurin decrease glycolysis and ATP levels of cancer cells. A) 
We measured lactate secretion into REN cells surnatant, an index of glycolytic flux,  and we see that it 
is significantly reduced in eIF6 depleted cell. B) We show that ATP content depends on eIF6 levels 
and Enzastaurin treatment, acute depletion of eIF6 and Enzastaurin treatment lead to a reduction of 
ATP levels of REN cells. 
 
 
In summary eIF6 activity is required for a glycolytic switch that may account for its need for 
tumor growth in vivo (Fig.26). 
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Figure 26. Simplified graphical summary of eIF6 activity in Malignant Pleural Mesothelioma. 
The translational rate increases during tumorigenesis. eIF6 expression and its activity could modulate 
protein synthesis, cell growth and metabolic status: in malignant mesothelioma, contribution of both 
eIF6 hyperexpression and eIF6 hyperphosphorylation improves protein synthesis, aerobic glycolysis 
and impaired cellular growth, giving rise to tumor development and malignancy. 
 
 
 
4.2 microRNAs subcellular distribution in MPM 
 
4.2.1 microRNAs association with polysomes define the subcellular 
distribution of miRNAs 
 
We hypothesize that miRNAs localization is essential to mediate oncogenic effect. In order to 
investigate which mRNAs are translationally regulated, we studied miRNAs association with 
polysomes using a density gradient sedimentation followed by high-throughput analysis of 
microRNAs in different fractions of the gradient, as depicted by Molotski and Soen. This 
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protocol extends the method of profiling mRNA association with polysomes (Arava 2003; 
Hendrickson, Hogan et al. 2009; Melamed, Eliyahu et al. 2009) to make it applicable to 
microRNAs (Molotski and Soen 2012). Performing polysomal profiles on REN cells, we 
collected the ribosome free (unbound) fraction into one pool and the lighter and heavier 
polysomal fractions into another two pools (Fig.27). We then isolated RNA from each pool 
and measured the levels of 799 miRNAs by nanoString nCounter system (nanoString, Seattle, 
Washington, USA). Profiling of miRNAs distribution in the translational machinery of REN 
cells indicates that 8% of miRNAs analysed are expressed in the polysomal pool.  Particularly 
some miRNAs present a different expression between subpolysomal and polysomal subsets 
(Figure 28). We hypothesize that miRNAs localization is essential to mediate their oncogenic 
function.  
 
 
 
Figure 27. Schematic of approach: analysis of microRNAs association with polysomes. We 
performed a polysomal profile and collected ribosome free (subpolysomes) and polysomes fractions. 
We pooled fractions as indicated, and isolated total RNA from each pool. RNA extracted has been 
processed by nCounter System for miRNA profiling analysis. 
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Figure 28. Subcellular distribution of microRNAs in REN cells.  Heatmap of microRNAs 
expressed in subpolysomal and polysomal fractions, in REN cells. We show that only 8% of miRNAs 
analysed are expressed in the polysomal pool and that some miRNAs present a different expression 
between subpolysomal and polysomal subsets. 
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4.2.2 microRNAs exhibit different ratios of association with polysomes 
 
The measurement of miRNAs polysomal association does not indicate the amount of 
microRNA in polysomes relative to its total amount in terms of quantitation, and the tendency 
of microRNAs to associate with the translational pool remains unknown as for the factors that 
influence this association. Our analysis reveals that five miRNAs are enriched on polysomes 
fractions. In order to try to give a measure of polysomal association, we calculated the 
microRNA polysome occupancy that denotes microRNA preferences for low, medium, or 
high association with polysomes. miRNAs occupancy is calculated by dividing each miRNA 
normalized level in the polysomal pool by the sum of its normalized levels in all the three 
pools (see fig. 27). We asked if miRNAs occupancy depends from miRNAs expression level 
in REN cells. Performing a correlation analysis, we found that miRNAs occupancy does not 
correlate with miRNAs expression level in REN cells, and that the bulk of miRNAs shows a 
medium occupancy (figure 29).  
 
 
 
Figure 29. miRNAs occupancy does not correlate with miRNAs expression level in REN cells      
Correlation analysis of miRNAs occupancy and expression levels in REN cells reveals that the bulk of 
miRNAs shows a medium occupancy, calculated by dividing each miRNA normalized level in the 
polysomal pool by the sum of its normalized levels in all the three pools. There is not a correlation  
between occupancy and expression levels in REN cells. 
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As the results obtained could be caused by random cosedimentation of polysomes and other 
rapidly sedimenting structures, extracts were pretreated with 30 mM EDTA, to dissociate 
ribosomes into subunits. As expected, this treatment disrupted the polysomes and resulted in a 
corresponding accumulation of 40S and 60S ribosomal subunits, as illustrated in figure 30.  
 
 
Figure 30. EDTA treatment causes the dissociation of ribosomes in single monosomes. Polysomal 
profile of REN cells after EDTA treatment: polysomes are completely distrupted and there is an 
accumulation of 40S and 60S ribosome subunits 
 
 
Concomitant with polysomes disaggregation, few miRNAs results EDTA insensitive, but 
most miRNAs are sensitive to EDTA treatment and shifted from heavy fractions to the top of 
the gradient, indicating that sedimentation of the miRNAs in the polysomal regions of 
gradients was not a result high molecular weight particle (figure 31).  
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Figure 31. miRNAs occupancy reflects cosedimentation with polysomes in REN cells.  After    
EDTA treatment we calculated miRNAs occupancy and we show most miRNAs are sensitive 
to EDTA treatment, although few miRNAs are insensitive 
 
 
Particularly, five miRNAs, let-7g-5p, miR-15b-5p, miR-16-5p, miR-191-5p and miR-24-3p 
show a high statistically significative difference of occupancy, EDTA-dependent. We 
hypothesize that the enrichment of miRNAs on polysomes could reflect their cosedimentation 
with actively translated mRNAs.  
 
4.2.3 Cell cycle pathways are related to miRNAs which are associated to 
polysomes 
 
We asked if the five polysomes associated miRNAs, and EDTA-sensitive, are related to 
common pathways or not. We relied to a bioinformatics analysis to disclose if all five 
miRNAs polysomes associated are able to target genes governing the same pathway. To this 
end we used miRSystem database [http://mirsystem.cgm.ntu.edu.tw/] to perform a functional 
annotation of all miRNAs expressed in the polysomal pool compared to the 5 polysome-
bound miRNAs. This study reveals that 217 pathways are specific for all miRNAs and 41 
pathways are specific for the polysome-bound subset (Figure 32A). As shown in figure 32B, 
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the 41 pathways indicated are specifically targeted by miRNAs that result associated to 
polysomes. Notably, it is evident that several components of cell cycle pathway are related to 
these microRNAs enriched on polysomes. 
 
 
Figure 32. Pathway prediction related to polysomes associated miRNAs indicates correlation 
with the cell cycle. A) Using miRSystem database [http://mirsystem.cgm.ntu.edu.tw/], the functional 
annotation of miRNAs expressed in the polysomal pool compared to 5 polysome-bound miRNAs 
reveals that 217 pathways are specific for all miRNAs and 41 pathways are specific for the polysome-
bound subset. B) We evidenced pathways targeted by the 5 miRNAs bound to polysomes and we 
releaved that cell cycle components (marked in green) are related to miRNAs polysomes associated 
 
Reid et al. reported that expression of the miR-15 family was consistently downregulated in 
MPM tumour specimens and cell lines. Growth inhibition caused by miR-16 correlated with 
downregulation of target genes including Bcl-2 and CCND1 (Reid, Pel et al. 2013). The miR-
15/16 family is downregulated and has tumour suppressor function in MPM. Taken together 
these data suggest that miRNAs polysomes localization could mediate their oncogenic or 
tumor suppressor function, regulating the expression of genes involved in cell cycle or 
tumorigenesis. 
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5 DISCUSSION 
 
Translation is a cellular process finely regulated during growth and development and it is 
deregulated in cancer cells. It has been shown that eukaryotic Initiation Factor 6 (eIF6) is a 
limiting factor in tumorigenesis, in vivo, regulating the availability of active 80S subunit, and 
that it is a key mediator in miRNA-mediated translational repression. It has been reported that 
it can associate with miRISC and that eIF6 knockdown abrogates miRNA-mediated 
regulation of target protein (Chendrimada, Finn et al. 2007). In this thesis we developed two 
research lines, with a common relevant factor, the translational regulation in malignant pleural 
Mesothelioma. We analyze the role of eIF6 in MPM growth and propose it as a new target of 
kinase inhibitors, and the subcellular distribution of microRNAs, particularly their association 
with actively translating polysomes. 
 
5.1 eIF6 in Malignant Pleural Mesothelioma 
 
We show that eIF6 is overexpressed and activated in malignant pleural mesothelioma, and 
that inhibition of its activity or phosphorylation reduces tumor burden and tumor growth. Our 
data further establish the deregulation of the translational machinery in mesothelioma cells, 
suggesting that this tumor is  peculiar in its capability to sustain translation, being insensitive 
to inhibition of the mTOR pathway (Ou, Moon et al. 2015). We will discuss our findings 
according to three lines: 1) the relevance for malignant mesothelioma, 2) the significance and 
feasibility to target eIF6, and 3) the molecular mechanism which may account for the 
increased eIF6 expression in mesothelioma. Malignant mesothelioma is distinguished into 
three morphological phenotypes, epithelial, sarcomatous and biphasic. Most tumors arise in 
the pleura and are epidemiologically linked to asbestos exposure. However, peritoneal 
mesothelioma also occurs, it is very rare and does not correlate with asbestos exposure 
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(Carbone, Ly et al. 2012). Malignant mesotheliomas originate as polyclonal tumors 
(Comertpay, Pastorino et al. 2014). Genetic analysis of abnormalities has displayed an 
heterogeneous mutational landscape with three predominating lesions, CDKN2A, NF2, BAP1 
(Sekido 2013). Thus, Malignant Pleural Mesothelioma can be classifying as a highly 
heterogeneous cancer. What is not heterogeneous is the (non) response to therapy. MPM is 
generally found to be resistant to conventional forms of therapy, such as cisplatinum and 
pemetrexed combination chemotherapy (Belli, Fennell et al. 2009). Therefore, tumor 
heterogeneity is the most relevant obstacle for applying targeted therapies to mesothelioma 
and conventional therapies do not work. Since the components of the translational apparatus 
integrate different oncogenic pathways, targeting its components may overcome the difficult 
of tumor heterogeneity. Moreover, tumoral cells exhibit an increase of the translational 
machinery suggesting “addiction” to high protein synthesis (Ruggero 2013). The fact that 
eIF6 is overexpressed and hyperphosphorylated in “MPM” suggests that it may be a good 
target.  
There is substantial body of evidence that eIF6 is rate-limiting for cancer cells.  First, 
overexpression of eIF6 is a driver of cancer. Enlargement of eIF6 containing nucleoli is a 
feature of aggressive colorectal tumors. Soft agar assay of eIF6
+/-
 mouse embryonic 
fibroblasts transduced with dominant negative p53 tumor suppressor plus H-rasV12 or with 
Myc plus H-rasV12 display a 70% reduction in transformed colonies, compared to the eIF6
+/+
 
mouse fibroblasts (Gandin, Miluzio et al. 2008). The tumorigenic potential of eIF6 is evident 
in a mouse model of lymphomagenesis, in vivo. In this model, expression of the Myc 
oncogene under the control of the enhancer of IgH (Eµ-Myc) in the B cells drives a lethal 
lymphoma, similar to B-cell lymphomas, with a median survival of only 4 months. Eµ-Myc/ 
eIF6
+/-
 mice show increased survival, and do not have overt negative phenotypes. Even in the 
p53
-/-
 genotype, where p53 deletion accelerates lymphomagenesis due to suppression of 
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apoptosis (Post, Quintas-Cardama et al. 2010), eIF6 depletion delays tumor development. 
Moreover, eIF6 is amplified in breast luminal cancers (Gatza, Silva et al. 2014). The 
phosphorylation of Ser235 residue on eIF6 is important for cancer development and 
transformation. eIF6 is controlled by the RACK1/PKCβ axis and led to initiation of 
translation. PRKCB is a target in lymphomas, and is expressed in mesotheliomas (Faoro, 
Loganathan et al. 2008). In our lab it has been showed that inhibition of eIF6 phosphorylation 
by genetic inactivation of Ser235 is a strategy to block eIF6 activity. Since eIF6 
phosphorylation is driven by the PKCβ axis, we proceeded to inhibit its activity with 
Enzastaurin (LY317615). Enzastaurin is an FDA approved potent and selective inhibitor of 
PKCβ; it exerts its antitumor effects by indirectly blocking tumor induced angiogenesis and 
by suppressing tumor cell proliferation and inducing apoptosis (Schwartzberg, Hermann et al. 
2014). Here we display that reducing eIF6 levels or treating cells with Enzastaurin, reduces 
MPM cell line growth, in vitro, and angiogenesis and tumor development in vivo, in an 
immunocompromised murine model. Questions are still open: in the long run eIF6 inhibition 
by Enzastaurin may not be effective because eIF6 has multiple phosphorylation sites in its C-
terminus, yet poorly characterized. Alternative strategies may be therefore required. Then, we 
have shown that eIF6 activity in cancer is necessary for dissociating inactive 80S subunits. In 
this context, several point mutations of eIF6 change the efficiency of eIF6 binding to 60S. 
Recent work from (Pesce, Minici et al. 2015) has led to the development of an antiassociation 
assay which may be used for screening inhibitors of eIF6 function, by small compounds 
chemical libraries. Similar approaches have been successful for other translation factors like 
eIF4G. Cancer cells are able to alter and reprogram their metabolism to acquire advantage for  
developing tumor. This alteration, called Warburg effect, consists of an increase in aerobic 
glycolysis, in conditions of high oxygen tension, and gives rise to augmented lactate 
production and ATP generation. Moreover, as well as producing more energy, tumor cells 
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increase lipids synthesis to build membranes during oncogenesis. In our lab, we had 
developed a transgenic mouse model where eIF6 heterozygous mice had approximately 50% 
of reduction of eIF6 protein. In this in vivo model, we found that eIF6 translational activity 
directs lipogenic program through the upregulation of enzymes involved in cholesterol and 
fatty acid synthesis. Specifically, the efficient translation of Fatty Acid Synthase (FASN), the 
key-player of de novo lipogenesis, is strictly correlated to eIF6 protein levels (Brina, Miluzio 
et al. 2015). In this thesis, we found that eIF6 depletion and its inactivation by Enzastaurin 
treatment significantly impair lactate and ATP production in MPM cells. Therefore, all these 
metabolic effects could partial justify the anti-cancer role of eIF6 inhibition. These data are 
intriguing and are in agreement with the observation that mutation of eIF6 Ser235 to Ala 
greatly reduces cancer growth in vivo, more efficiently than in vitro. Since the effects of eIF6 
depletion on polysomal accumulation are significant, but modest, we expect that specific 
mRNAs might be regulated by eIF6 activity, at the translational level in REN cells. It will be 
of particular interest applying to mesothelioma tissues novel technologies as ribosome 
profiling, in order to isolate them. In conclusion of the first part of this work, we suggest that 
modulation of eIF6 levels and activity may lead to a therapeutical strategy in tumor therapy, 
especially where eIF4E inhibition by rapalogs is not effective, as in MPM. 
 
5.2 microRNAs in MPM 
 
 
Several studies demonstrated that miRNA expression in MPM is highly variable (Truini, 
Coco et al. 2014). Early studies profiling the microRNAs expression in MPM identified many 
changes which affect the reduced response to apoptotic signals, rates of metabolism and 
proliferation, enhanced migration and invasion (Guled, Lahti et al. 2009; Busacca, Germano 
et al. 2010). Particularly, it has been demonstrated that overexpression of miR-29c-5p, 
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downregulated in MPM cell lines, is able to inhibit proliferation and invasion of MPM cell 
lines, in vitro (Pass, Goparaju et al. 2010). Moreover miR-31 expression is reduced in MPM 
cell lines, simultaneously with deletion of the CDKN2A gene (Ivanov, Goparaju et al. 2010). 
Re-expressing miR-31 led to reduced proliferation, migration and invasion by cell cycle 
arrest. Another miRNA with inhibitory effect on proliferation in MPM is let-7a that acts 
attenuating RAS signaling (Johnson, Grosshans et al. 2005); its tumor suppressor functions 
was demonstrated in lung cancer. The miR-15 family has also been shown to be 
downregulated in MPM (Aqeilan, Calin et al. 2010), regulating cell cycle and anti-apoptotic 
genes. The members of this family (miR-15a, miR-15b, miR-16 and miR-195) were found at 
significantly lower level in MPM samples (Reid, Pel et al. 2013). First, because the 
association of eIf6 with miRISC has been seen and it has been demonstrated that it is able to 
disrupt polysomes formation through the inhibition of 80S complex assembly and,second,  
since the knockdown of eIF6 abrogates miRNA-mediated regulation of target protein and 
mRNA levels (Chendrimada, Finn et al. 2007), we decided to identify the localization of 
miRNAs in RNA subpopulations in MPM. The last 5 years has seen a rapid advance in the 
study of the role of microRNAs in MPM biology, linking them to MPM growth, invasion, 
migration and drug resistance, but the actual knowledge led to conflicting data. Analysis of 
sublocalization of miRNAs could therefore give us an idea of how the little RNAs regulate 
their target genes. We have shown that, at steady state, not all miRNAs expressed in 
exponentially REN cells cosediment with polyribosomes, but only 8%; in addition most of 
them are sensitive to EDTA presence. The observed localization of miRNAs on polysomes is 
consistent with several previous studies. The mRNA targets of the members of the miRNA 
family in Caenorhabditis elegans were shown to be in polysomes (Seggerson, Tang et al. 
2002), and subsequent studies showed that the bulk of miRNAs in Drosophila melanogaster 
cells and in C. elegans sediment with ribosomes (Caudy, Ketting et al. 2003). Today, it is 
83 
 
unclear whether microRNAs have distinct tendencies for associating with polysomes and 
whether these tendencies are influenced by properties of the microRNA or the cellular 
context. In our work we measure polysome occupancy of microRNAs, that represents the 
high, medium or low preference of a miRNAs to associate with polysomes, and we showed 
that the bulk of miRNAs have a medium occupancy. We don’t know, actually, if the observed 
preference of individual microRNAs for association with polysomes is similar in all MPM 
cell lines, and if it is independent of the abundance of the microRNAs. Previous work in HeLa 
cells reported copurification with polysomes of three randomly chosen microRNAs (let-7, 
mir-21, and miR-16) and hypothesized that association with polysomes is general for most 
microRNAs (Maroney et al. 2006). Molotoski and Soen showed, instead, that the degree of 
microRNA association with polysomes is microRNA-specific (Molotski and Soen 2012). 
Here we showed also that there is not a correlation between miRNA occupancy and their 
cellular expression level, and we evidenced 5 miRNAs (let-7g-5p; miR-15b-5p; miR-16-5p; 
miR-191-5p; miR-24-3p) that show a significative difference of occupancy after treatment 
with EDTA, suggesting that this cosedimentation could result from the association of 
miRNAs with their target, and not with the RNPs. In particular, analyzing the common 
predicted target genes of these 5 miRNAs we evidence that the cell cycle pathways are related 
to miRNAs which are associated to polysomes, confirming the study performed by Reid et al, 
which link miR-15 family to Bcl2 and anti-apoptotic genes in MPM. Since the significance of 
association of microRNAs with polysomes has been hypothesized to reflect involvement in 
translation repression, we can hypothesize that the evidenced miRNAs could regulate 
translation of cell cycle genes binding mRNA actively translated in MPM. Further studies are 
required to address this question. 
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